

Supporting Information

Pd-Catalyzed Stereoretentive Synthesis of Reversed C-Acyl Glycosides: Access to Rare L-Sugars and Higher-Carbon Sugars

Guoqiang Cheng,^{a,b} Bo Yang,^{a,b*} and Feng Zhu^{a,b,c*}

^aFrontiers Science Center for Transformative Molecules (FSCTM), Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China; ^bPingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Henan Normal University, Xinxiang, Henan 453007, P.R. China; ^cState Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, China

*yangbo71@sjtu.edu.cn

*fzchem@sjtu.edu.cn

Table of Contents

1. General Information	3
2. General Procedures	4
3. Additional Reaction Optimization Conditions	5
4. Stereochemical Integrity of the Reversed Glycosyl Stannane	7
5. Detailed Experimental Procedures for Compounds 12-42	8
6. Detailed Experimental Procedures for Compounds S1-S11	43
7. References	48
8. Copies of 1D and 2D NMR Spectra	49

1. General Information

Commercially available materials were used as received without further purification unless otherwise noted. All reactions were carried out under anhydrous N₂ in oven-dried glassware. Pd₂(dba)₃ (98% purity) were purchased from Leyan. CuCl were purchased from Sigma-Aldrich. Anhydrous 1,4-dioxane (99.5% purity) were purchased from Adamas. Visualizations were performed with UV light and/or Hanessian stain and/or sulfuric acid stain (5% H₂SO₄ in MeOH). Column chromatography was performed on silica gel (200-400 mesh). Automated column chromatography was performed on a Biotage Selekt using Silicycle high-resolution SiO₂ cartridges unless otherwise noted. ¹H and ¹³C NMR spectra were recorded on Bruker 400/500 MHz instruments and were reported as follows: chemical shift (δ), multiplicity (s = singlet, d = doublet, t = triplet, q =quartet, br = broad, m = multiplet), coupling constants (Hz), and integration. The residual solvent reference peaks were used from published literature. 2D NMR experiments were performed using standard parameters (*200 and More NMR Experiments*, S. Berger, S. Braun, Wiley-VCH, **2004**). High-resolution mass spectra (HR-MS) were recorded on a Waters Micromass Q-ToF Premier mass spectrometer. Optical rotations were measured on an Anton Paar MCP 5500 automatic polarimeter using a 100 mm path-length cell at 589 nm and were reported as an average of five data points. Thin layer chromatography was used to monitor reaction progress and analyze fractions from column chromatography.

2. General Procedures

General Procedure A for Cross-Coupling Reactions.

To a solution of non-classical anomeric stannane (2.0 equiv) and thioester (1.0 equiv) in anh. 1,4-dioxane (2.00 mL), Pd₂(dba)₃ (2.5 mol%), ligand **L6** (10 mol%), CuCl (1.0 equiv) were added. The reaction mixture was placed under Ar, heated at 90 °C using a metal heating block for the indicated period of time, cooled to rt, filtered through a pad of Celite®, and concentrated. ¹H NMR spectra were recorded using this mixture to evaluate diastereoselectivity. The crude material was purified by column chromatography on SiO₂.


General Procedure B for Preparation of Thioesters

Under N₂, RCOOH (1.00 equiv), Ph₂S₂ (1.10 equiv), and anh. CH₂Cl₂ were successively added into a flame-dried glassware. The mixture was cooled to 0 °C, P(*n*-Bu)₃ (1.20 equiv) was added drop-wise. After stirring for the time indicated at rt, the reaction was concentrated and directly purified by column chromatography on SiO₂ to yield the thioester product.



General Procedure C for Preparing Pyranosyl Stannanes

To a solution of 4-deoxypentenose (1.0 equiv) in a cooled (0 °C), vigorously stirring biphasic solution of DCM, saturated aq. NaHCO₃, and acetone, a solution of Oxone® (4.0 equiv) in H₂O was added dropwise over 15 min. The mixture was stirred at 0 °C for 0.5 h, then at rt for 2 h. The organic phase was then separated, and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄) and concentrated to afford the crude epoxide. The crude epoxide (1.0 equiv) was dissolved in anhydrous and degassed THF, cooled to -15 °C, and a solution of MeMgSnBu₃ (1.5 equiv) in THF was added. The reaction was stirred at -15 °C for 1.5 h, then warmed to -10 °C and stirred for 1 h, quenched with H₂O, filtered twice through Celite®, and the organic phase was separated. The aqueous phase was extracted with CH₂Cl₂, and the combined organic layers were dried (Na₂SO₄), concentrated, and purified by column chromatography on SiO₂.

3. Additional Reaction Optimization Conditions




Entry	Ligand	NMR yield
1	L1	32%
2	L2	63%
3	L3	71%
4	L4	72%
5	L5	82%
6	L6	86%




Entry	Cu salts	NMR yield
1	CuCl	85%
2	CuBr	60%
3	CuI	9%
4	----	None

Table 3 Screening of acylating reagents



Entry	Acylating reagents	NMR yield
1	X = SPh	85%
2	X = Cl	42%
3	X = OCOPh	67%


4. Stereochemical Integrity of the Reversed Glycosyl Stannane



To a solution of tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane **9a**¹ (72.4 mg, 0.100 mmol) in anh. 1,4-dioxane (2.00 mL), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) were added. The reaction mixture was placed under Ar, heated at 90 °C using a metal heating block for 12 h, cooled to rt, filtered through a pad of Celite®, and concentrated. ¹H NMR spectra were recorded using this mixture to evaluate diastereoselectivity. The crude material was purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 15:1) to afford **9a** (35.1 mg, 49%) as a colorless oil and (2*S*,3*R*,4*S*)-3,4-bis(benzyloxy)-2-methoxy-3,4-dihydro-2*H*-pyran² (5.60 mg, 17%) as a colorless oil.


No evidence of configurational inversion at the anomeric center was observed, indicating that the stereochemical configuration of **9a** remains intact under the transmetalation conditions. Although a minor β-O elimination side reaction was detected, this pathway does not compromise the stereochemical integrity of the anomeric center.

5. Detailed Experimental Procedures for Compounds 12-42




Phenyl((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (**12a**).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl benzothioate (21.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 6:1) **12a** (43.3 mg, 80%) as a colorless oil: $[\alpha]_D^{20} = +29.3$ ($c = 2.15$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.03 (d, $J = 7.7$ Hz, 2H), 7.55 (t, $J = 7.3$ Hz, 1H), 7.48 – 7.27 (m, 17H), 5.01 (d, $J = 4.3$ Hz, 1H, H-5), 4.79 – 4.71 (m, 6H), 4.66 (d, $J = 11.9$ Hz, 1H), 4.54 – 4.53 (m, 1H), 4.13 (dd, $J = 8.4, 2.3$ Hz, 1H), 3.97 (dd, $J = 8.4, 2.2$ Hz, 1H), 2.90 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 197.0, 138.8, 138.7, 138.3, 135.5, 133.1, 129.4, 128.5, 128.4$ (2), 128.1, 128.0, 127.9, 127.8, 127.7 (2), 101.8, 75.9, 75.6, 75.5, 74.3, 73.8, 73.4, 73.3, 57.8; HRMS (ESI) m/z calcd for C₃₄H₃₄O₆Na [M + Na]⁺ 561.2253, found 561.2250.



(4-Methoxyphenyl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (**12b**).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **12b** (54.4 mg, 96%) as a colorless oil: $[\alpha]_D^{20} = +32.7$ ($c = 2.10$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.03 (d, $J = 8.3$ Hz, 2H), 7.41 – 7.26 (m, 15H), 6.93 (d, $J = 8.3$ Hz, 2H), 4.97 (d, $J = 4.1$ Hz, 1H, H-5), 4.78 – 4.71 (m, 6H), 4.65 (d, $J = 11.9$ Hz, 1H), 4.52 – 4.50 (m, 1H), 4.13 (d, $J = 8.1$ Hz, 1H), 3.95 (d, $J = 8.1$ Hz, 1H), 3.86 (s, 3H), 2.96 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 195.4, 163.4, 138.8$ (2), 138.4, 131.7, 128.6, 128.4 (2), 128.1, 128.0, 127.8, 127.7 (2), 127.6, 113.6, 101.7, 75.9, 75.6, 75.5, 74.3, 73.7, 73.3, 73.2, 57.8, 55.5; HRMS (ESI) m/z calcd for C₃₅H₃₆O₇Na [M + Na]⁺ 591.2359, found 591.2354.



12c

(4-(Trifluoromethyl)phenyl)((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)methanone (12c).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-(trifluoromethyl)benzothioate (28.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 6:1) **12c** (56.0 mg, 92%) as a colorless oil: $[α]_D^{20} = +24.0$ (c = 2.17, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.13 (d, *J* = 8.1 Hz, 2H), 7.71 (d, *J* = 8.1 Hz, 2H), 7.40 – 7.29 (m, 15H), 4.98 (d, *J* = 4.8 Hz, 1H, H-5), 4.77 – 4.72 (m, 6H), 4.61 (d, *J* = 11.8 Hz, 1H), 4.50 – 4.48 (m, 1H), 4.08 (dd, *J* = 8.2, 2.9 Hz, 1H), 3.95 (dd, *J* = 8.1, 2.7 Hz, 1H), 2.94 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 196.0, 138.6 (2), 138.2, 138.0, 134.3 (q, *J* = 32.5 Hz), 129.7, 128.5 (2), 128.2, 128.0, 127.9 (2), 127.8, 125.5 (q, *J* = 3.5 Hz), 123.7 (q, *J* = 272.7 Hz), 101.9, 75.9, 75.8, 75.1, 74.0, 73.9, 73.5, 73.2, 58.0; ¹⁹F NMR (471 MHz, CDCl₃) δ = -63.1; HRMS (ESI) *m/z* calcd for C₃₅H₃₃O₆F₃Na [M + Na]⁺ 629.2127, found 629.2121.



12d

[1,1'-Biphenyl]-4-yl((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)methanone (12d).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl [1,1'-biphenyl]-4-carbthioate (29.0 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) **12d** (39.3 mg, 64%) as a colorless oil: $[α]_D^{20} = +25.8$ (c = 1.77, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.11 (d, *J* = 7.9 Hz, 2H), 7.69 (d, *J* = 7.9 Hz, 2H), 7.65 (d, *J* = 7.6 Hz, 2H), 7.50 – 7.29 (m, 18H), 5.04 (d, *J* = 4.4 Hz, 1H, H-5), 4.77 – 4.72 (m, 6H), 4.66 (d, *J* = 11.8 Hz, 1H), 4.55 – 4.53 (m, 1H), 4.14 (d, *J* = 8.1 Hz, 1H), 3.97 (d, *J* = 8.2 Hz, 1H), 2.98 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 196.6, 145.6, 139.9, 138.8 (2), 138.3, 134.3, 130.0, 129.1, 128.5 (3), 128.4, 128.2, 128.0, 127.9, 127.8 (2), 127.7, 127.3, 127.1, 101.8, 76.0, 75.8, 75.5, 74.4, 73.8, 73.4, 73.3, 57.9; HRMS (ESI) *m/z* calcd for C₄₀H₃₈O₆Na [M + Na]⁺ 637.2566, found 637.2562.



12e

Naphthalen-2-yl((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12e).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl naphthalene-2-carbothioate (26.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) **12e** (53.1 mg, 90%) as a colorless oil: $[\alpha]_D^{20} = +21.9$ (*c* = 2.70, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.61 (s, 1H), 8.08 (dd, *J* = 8.7, 1.4 Hz, 1H), 7.95 – 7.87 (m, 3H), 7.61 (t, *J* = 7.5 Hz, 1H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.45 – 7.26 (m, 15H), 5.17 (d, *J* = 4.4 Hz, 1H, H-5), 4.81 – 4.73 (m, 6H), 4.69 (d, *J* = 11.9 Hz, 1H), 4.61 – 4.59 (m, 1H), 4.20 (dd, *J* = 8.3, 2.8 Hz, 1H), 4.01 (dd, *J* = 8.3, 2.7 Hz, 1H), 2.87 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 197.0, 138.8 (2), 138.3, 135.6, 132.8, 132.5, 131.4, 129.8, 128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8 (2), 127.7 (2), 126.8, 124.8, 101.8, 76.0, 75.8, 75.6, 74.4, 73.8, 73.4, 73.3, 57.9; HRMS (ESI) *m/z* calcd for C₃₈H₃₆O₆Na [M + Na]⁺ 611.2410, found 611.2402.



12f

(4-Benzoylphenyl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12f).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-benzoylbenzothioate **S1** (31.8 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12f** (59.5 mg, 93%) as a colorless oil: $[\alpha]_D^{20} = +19.4$ (*c* = 3.20, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.13 (d, *J* = 7.9 Hz, 2H), 7.86 (d, *J* = 8.0 Hz, 2H), 7.80 (d, *J* = 8.0 Hz, 2H), 7.63 (t, *J* = 7.2 Hz, 1H), 7.53 – 7.28 (m, 17H), 5.03 (d, *J* = 4.7 Hz, 1H, H-5), 4.77 – 4.72 (m, 6H), 4.64 (d, *J* = 11.8 Hz, 1H), 4.53 – 4.51 (m, 1H), 4.09 (dd, *J* = 8.1, 2.9 Hz, 1H), 3.95 (dd, *J* = 8.2, 2.7 Hz, 1H), 2.98 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 196.4, 196.0, 141.1, 138.6, 138.1 (2), 137.0, 133.1, 130.1, 129.9, 129.2, 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8 (2), 127.7, 101.8, 75.8 (2), 75.2, 74.1, 73.9, 73.4, 73.2, 58.0; HRMS (ESI) *m/z* calcd for C₄₁H₃₈O₇Na [M + Na]⁺ 665.2515, found 665.2507.




12g

(4-Fluorophenyl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12g).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-


fluorobenzothioate (23.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) **12g** (54.3 mg, 98%) as a colorless oil: $[\alpha]_D^{20} = +26.2$ (c = 2.78, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.09 – 8.06 (m, 2H), 7.40 – 7.28 (m, 15H), 7.14 – 7.11 (m, 2H), 4.96 (d, *J* = 4.7 Hz, 1H, H-5), 4.77 – 4.71 (m, 6H), 4.63 (d, *J* = 11.8 Hz, 1H), 4.50 – 4.49 (m, 1H), 4.10 (dd, *J* = 8.2, 3.0 Hz, 1H), 3.95 (dd, *J* = 8.2, 2.9 Hz, 1H), 2.96 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 195.3, 165.6 (d, *J* = 255.0 Hz), 138.7, 138.2, 132.1 (d, *J* = 9.2 Hz), 131.9 (d, *J* = 2.9 Hz), 128.5, 128.1, 128.0, 127.9, 127.8 (2), 127.7, 115.6 (d, *J* = 21.8 Hz), 101.8, 75.8, 75.7, 75.3, 74.2, 73.8, 73.4, 73.2, 57.9; ¹⁹F NMR (471 MHz, CDCl₃) δ = -104.8; HRMS (ESI) *m/z* calcd for C₃₄H₃₃O₆FNa [M + Na]⁺ 579.2159, found 579.2159.



12h

(4-Chlorophenyl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12h).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-chlorobenzothioate (24.9 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) **12h** (53.4 mg, 93%) as a colorless oil: $[\alpha]_D^{20} = +27.5$ (c = 1.98, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.97 (d, *J* = 8.5 Hz, 2H), 7.43 – 7.27 (m, 17H), 4.94 (d, *J* = 4.8 Hz, 1H, H-5), 4.76 – 4.71 (m, 6H), 4.61 (d, *J* = 11.8 Hz, 1H), 4.48 (dd, *J* = 4.8, 3.0 Hz, 1H), 4.08 (dd, *J* = 8.1, 3.0 Hz, 1H), 3.94 (dd, *J* = 8.1, 2.7 Hz, 1H), 2.97 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 195.7, 139.5, 138.7, 138.2, 133.9, 130.8, 128.8, 128.5, 128.1, 128.0, 127.9, 127.8 (2), 127.7, 101.8, 75.8 (2), 75.3, 74.2, 73.8, 73.4, 73.2, 57.9; HRMS (ESI) *m/z* calcd for C₃₄H₃₃O₆ClNa [M + Na]⁺ 595.1863, found 595.1856.




12i

(4-Phenoxyphenyl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12i).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-phenoxybenzothioate **S2** (30.6 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) **12i** (59.1 mg, 94%) as a colorless oil: $[\alpha]_D^{20} = +31.4$ (c = 2.97, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.05 (d, *J* = 8.7 Hz, 2H), 7.43 – 7.28 (m, 17H), 7.22 (t, *J* = 7.4 Hz, 1H), 7.09 (d, *J* = 8.1 Hz, 2H), 7.01 (d, *J* = 8.7 Hz, 2H), 4.98 (d, *J* = 4.8 Hz, 1H, H-5), 4.79 – 4.72 (m, 6H), 4.65 (d, *J* = 11.9 Hz,


1H), 4.52 – 4.51 (m, 1H), 4.13 (dd, $J = 8.1, 3.0$ Hz, 1H), 3.96 (dd, $J = 8.1, 2.7$ Hz, 1H), 3.03 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) $\delta = 195.4, 161.9, 155.5, 138.7, 138.3, 131.7, 130.2, 130.1, 128.4$ (3), 128.1, 127.9, 127.8 (2), 127.7 (2), 124.7, 120.3, 117.2, 101.7, 75.9, 75.7, 75.4, 74.3, 73.8, 73.4, 73.2, 57.8; HRMS (ESI) m/z calcd for $\text{C}_{40}\text{H}_{38}\text{O}_7\text{Na}$ $[\text{M} + \text{Na}]^+$ 653.2515, found 653.2509.



12j

Methyl 4-((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-carbonyl)benzoate (12j).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), methyl 4-((phenylthio)carbonyl)benzoate (27.2 mg, 0.100 mmol), $\text{Pd}_2(\text{dba})_3$ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO_2 (Hexanes:EtOAc, 4:1) **12j** (52.8 mg, 88%) as a colorless oil: $[\alpha]_D^{20} = +24.0$ ($c = 2.48, \text{CHCl}_3$); ^1H NMR (500 MHz, CDCl_3) δ 8.13 – 8.06 (m, 4H), 7.40 – 7.27 (m, 15H), 4.99 (d, $J = 4.1$ Hz, 1H, H-5), 4.77 – 4.70 (m, 6H), 4.64 (d, $J = 11.8$ Hz, 1H), 4.51 – 4.50 (m, 1H), 4.08 (d, $J = 8.2$ Hz, 1H), 3.96 – 3.94 (m, 4H), 2.89 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) $\delta = 196.5, 166.3, 138.8, 138.6$ (2), 138.2, 133.7, 129.7, 129.3, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8 (2), 127.7, 101.9, 75.8 (2), 75.3, 74.2, 73.8, 73.4, 73.3, 57.9, 52.5; HRMS (ESI) m/z calcd for $\text{C}_{36}\text{H}_{36}\text{O}_8\text{Na}$ $[\text{M} + \text{Na}]^+$ 619.2308, found 619.2303.



12k

4-((2R,3R,4S,5R,6S)-3,4,5-Tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-carbonyl)benzotrile (12k).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-cyanobenzothioate (23.9 mg, 0.100 mmol), $\text{Pd}_2(\text{dba})_3$ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO_2 (Hexanes:EtOAc, 4:1) **12k** (53.7 mg, 95%) as a white solid: $[\alpha]_D^{20} = +23.4$ ($c = 2.44, \text{CHCl}_3$); ^1H NMR (500 MHz, CDCl_3) δ 8.10 (d, $J = 8.4$ Hz, 2H), 7.73 (d, $J = 8.4$ Hz, 2H), 7.39 – 7.28 (m, 15H), 4.95 (d, $J = 5.2$ Hz, 1H, H-5), 4.74 – 4.69 (m, 6H), 4.58 (d, $J = 11.8$ Hz, 1H), 4.45 (dd, $J = 5.0, 3.0$ Hz, 1H), 4.04 (dd, $J = 7.9, 2.9$ Hz, 1H), 3.92 (dd, $J = 7.9, 2.5$ Hz, 1H), 2.97 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) $\delta = 195.6, 138.5$ (2), 137.9, 132.3, 129.7, 128.5 (2), 128.1, 128.0, 127.9 (3), 127.8, 118.0, 116.2, 101.8, 75.9, 75.7, 74.9, 73.9 (2), 73.4, 73.1, 58.0; HRMS (ESI) m/z calcd for $\text{C}_{35}\text{H}_{33}\text{NO}_6\text{Na}$ $[\text{M} + \text{Na}]^+$ 586.2206, found 586.2200.



12l

***o*-Tolyl((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12l).**


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 2-methylbenzothioate (22.8 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) **12l** (47.0 mg, 85%) as a colorless oil: $[\alpha]_D^{20} = +33.1$ ($c = 2.23$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.73 (d, $J = 7.8$ Hz, 1H), 7.41 – 7.23 (m, 18H), 4.98 (d, $J = 3.8$ Hz, 1H, H-5), 4.80 – 4.76 (m, 4H), 4.70 – 4.66 (m, 2H), 4.64 – 4.62 (m, 1H), 4.60 (d, $J = 3.0$ Hz, 1H), 4.07 (dd, $J = 9.0, 2.6$ Hz, 1H), 3.97 (dd, $J = 9.0, 2.9$ Hz, 1H), 2.78 (s, 3H), 2.51 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 200.2, 140.1, 138.8, 138.7, 138.4, 135.1, 132.1, 131.7, 130.5, 128.5$ (2), 128.4, 128.1, 127.8, 127.6, 125.4, 101.9, 76.4, 75.8, 75.3, 74.4, 74.0, 73.4, 73.2, 57.7, 21.5; HRMS (ESI) m/z calcd for C₃₅H₃₆O₆Na [M + Na]⁺ 575.2410, found 575.2407.



12m

(1-Methyl-1*H*-indol-5-yl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12m).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 1-methyl-1*H*-indole-5-carbthioate **S3** (26.7 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 2:1) **12m** (47.1 mg, 80%) as a yellow oil: $[\alpha]_D^{20} = +33.1$ ($c = 1.41$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.41 (s, 1H), 7.95 (d, $J = 8.6$ Hz, 1H), 7.42 – 7.26 (m, 16H), 7.10 (s, 1H), 6.59 (s, 1H), 5.13 (br, 1H, H-5), 4.78 – 4.66 (m, 7H), 4.58 – 4.55 (m, 1H), 4.21 (d, $J = 8.2$ Hz, 1H), 3.98 (d, $J = 8.3$ Hz, 1H), 3.81 (s, 3H), 2.86 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 196.9, 139.2, 139.0, 138.9, 138.6, 130.4, 128.4$ (2), 128.1, 128.0, 127.9, 127.7, 127.6, 124.4, 122.9, 109.1, 103.3, 101.7, 76.1, 75.8, 75.7, 74.7, 73.7, 73.4, 73.3, 57.8, 33.1; HRMS (ESI) m/z calcd for C₃₇H₃₇NO₆Na [M + Na]⁺ 614.2519, found 614.2513.



12n

Benzo[*d*]oxazol-6-yl((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12n).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl benzo[*d*]oxazole-6-carbothioate **S4** (25.5 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 2:1) **12n** (44.8 mg, 77%) as a yellow oil: $[\alpha]_D^{20} = +25.8$ (*c* = 2.20, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.30 (s, 1H), 8.23 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 1H), 7.84 (d, *J* = 8.4 Hz, 1H), 7.40 – 7.26 (m, 15H), 5.04 (d, *J* = 4.6 Hz, 1H, H-5), 4.76 – 4.71 (m, 6H), 4.62 (d, *J* = 11.8 Hz, 1H), 4.52 – 4.50 (m, 1H), 4.11 (d, *J* = 8.0 Hz, 1H), 3.95 (d, *J* = 8.0 Hz, 1H), 2.93 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 195.7, 155.3, 149.9, 143.8, 138.7, 138.6, 138.2, 133.3, 128.5, 128.4 (2), 128.1, 128.0, 127.9, 127.8 (2), 127.7, 126.3, 120.4, 112.5, 101.8, 75.9 (2), 75.3, 74.3, 73.8, 73.4, 73.2, 57.9; HRMS (ESI) *m/z* calcd for C₃₅H₃₃NO₇Na [M + Na]⁺ 602.2155, found 602.2152.



12o

Furan-2-yl((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (12o).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl furan-2-carbothioate (20.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 2:1) **12o** (48.7 mg, 92%) as a white solid: $[\alpha]_D^{20} = +36.9$ (*c* = 2.22, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.62 (s, 1H), 7.37 – 7.23 (m, 16H), 6.51 – 6.50 (m, 1H), 4.81 – 4.65 (m, 6H), 4.58 (d, *J* = 11.8 Hz, 1H), 4.52 (d, *J* = 11.8 Hz, 1H), 4.33 (dd, *J* = 6.2, 2.5 Hz, 1H), 4.01 (dd, *J* = 7.0, 2.8 Hz, 1H), 3.84 (dd, *J* = 6.8, 2.2 Hz, 1H), 3.24 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 185.1, 151.1, 146.8, 138.7, 138.5, 138.0, 128.4 (3), 128.1, 127.9 (2), 127.8 (2), 127.7, 119.9, 112.2, 101.4, 75.8, 75.7, 74.9, 74.1, 73.8, 73.4, 72.8, 57.6; HRMS (ESI) *m/z* calcd for C₃₂H₃₂O₇Na [M + Na]⁺ 551.2046, found 551.2042.




12p

1,4-Phenylenebis(((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone) (12p).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (289 mg, 0.400 mmol), *S,S*-diphenyl benzene-1,4-bis(carbothioate) (35.0 mg, 0.100 mmol), Pd₂(dba)₃ (4.60 mg, 0.005 mmol), ligand **L6** (15.90 mg, 0.020 mmol), CuCl (19.80 mg, 0.200 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 2:1) **12p** (83.9 mg,


84%) as a colorless oil: $[\alpha]_D^{20} = +28.2$ ($c = 3.62$, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.10 (s, 4H), 7.42 – 7.28 (m, 30H), 5.01 (d, $J = 4.8$ Hz, 2H, H-5), 4.77 – 4.69 (m, 12H), 4.66 (d, $J = 11.8$ Hz, 2H), 4.50 (dd, $J = 4.6, 3.1$ Hz, 2H), 4.08 (dd, $J = 8.0, 2.8$ Hz, 2H), 3.95 (dd, $J = 8.1, 2.5$ Hz, 2H), 2.93 (s, 6H); $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 196.3, 138.6, 138.5, 138.1, 129.3, 128.5, 128.4, 128.1, 127.9$ (2), 127.8 (2), $127.7, 101.8, 75.7, 75.6, 75.2, 74.1, 73.8, 73.4, 73.2, 57.8$; HRMS (ESI) m/z calcd for $\text{C}_{62}\text{H}_{62}\text{O}_{12}\text{Na}$ $[\text{M} + \text{Na}]^+$ 1021.4139, found 1021.4118.



12q

(*E*)-3-Phenyl-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)prop-2-en-1-one (12q).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-(*p*-tolyl) (*E*)-3-phenylprop-2-enethioate (25.4 mg, 0.100 mmol), $\text{Pd}_2(\text{dba})_3$ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO_2 (Hexanes:EtOAc, 4:1) **12q** (38.8 mg, 69%) as a pale yellow oil: $[\alpha]_D^{20} = +5.53$ ($c = 1.62$, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.71 (d, $J = 16.1$ Hz, 1H), 7.57 – 7.56 (m, 2H), 7.40 – 7.23 (m, 18H), 7.07 (d, $J = 16.1$ Hz, 1H), 4.80 – 4.67 (m, 5H), 4.62 (d, $J = 11.9$ Hz, 1H), 4.54 (d, $J = 11.9$ Hz, 1H), 4.51 (d, $J = 5.9$ Hz, 1H, H-5), 4.32 (dd, $J = 5.4, 2.5$ Hz, 1H), 3.97 (dd, $J = 7.3, 2.8$ Hz, 1H), 3.88 (dd, $J = 7.3, 2.3$ Hz, 1H), 3.42 (s, 3H); $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 196.3, 143.3, 138.7, 138.6, 138.1, 134.7, 130.6, 129.0, 128.6, 128.5$ (2), $128.2, 128.0, 127.9, 127.8$ (3), $123.0, 101.5, 78.0, 75.8, 74.9, 74.2, 73.8, 73.3, 72.9, 58.3$; HRMS (ESI) m/z calcd for $\text{C}_{36}\text{H}_{36}\text{O}_6\text{Na}$ $[\text{M} + \text{Na}]^+$ 587.2410, found 587.2408.




12r

2,2-Diphenyl-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-one (12r).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 2,2-diphenylethanethioate (30.4 mg, 0.100 mmol), $\text{Pd}_2(\text{dba})_3$ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO_2 (Hexanes:EtOAc, 4:1) **12r** (60.6 mg, 96%) as a white solid: $[\alpha]_D^{20} = +60.8$ ($c = 2.31$, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.33 – 7.16 (m, 25H), 5.68 (s, 1H), 4.77 (d, $J = 12.4$ Hz, 1H), 4.70 (d, $J = 1.9$ Hz, 1H), 4.58 (d, $J = 12.0$ Hz, 1H), 4.53 (d, $J = 12.4$ Hz, 1H), 4.46 (d, $J = 12.0$ Hz, 1H), 4.38 (d, $J = 7.8$ Hz, 1H, H-5), 4.26 (d, $J = 11.5$ Hz, 1H), 4.21 (d, $J = 11.5$ Hz, 1H), 4.09 (dd, $J = 7.8, 2.7$ Hz, 1H), 3.76 (dd, $J = 5.7, 2.9$ Hz, 1H), 3.67 (dd, $J = 5.8, 1.8$ Hz, 1H), 3.40 (s, 3H); $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 204.9, 138.6$ (2), 138.3 (2), $138.0, 129.5, 129.3, 128.8, 128.5$ (2), $128.4, 128.0, 127.9$ (2), 127.8 (2), $127.7,$


127.2, 127.1, 101.0, 76.7, 75.7, 74.3, 74.2, 73.8, 73.2, 72.4, 59.9, 57.9; HRMS (ESI) m/z calcd for $C_{41}H_{40}O_6Na$ $[M + Na]^+$ 651.2723, found 651.2720.



12s

3-Phenyl-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)propan-1-one (12s).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 3-phenylpropanethioate (24.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 6:1) **12s** (52.8 mg, 93%) as a colorless oil: $[\alpha]_D^{20} = +50.2$ ($c = 2.15$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.18 (m, 20H), 4.78 (d, $J = 12.4$ Hz, 1H), 4.76 (d, $J = 1.8$ Hz, 1H), 4.63 (d, $J = 11.9$ Hz, 1H), 4.58 (d, $J = 12.4$ Hz, 1H), 4.54 (d, $J = 11.9$ Hz, 1H), 4.41 (d, $J = 11.7$ Hz, 1H), 4.38 (d, $J = 11.8$ Hz, 1H), 4.23 (d, $J = 7.8$ Hz, 1H, H-5), 4.06 (dd, $J = 7.8, 2.9$ Hz, 1H), 3.80 (dd, $J = 5.7, 2.9$ Hz, 1H), 3.71 (dd, $J = 5.8, 1.7$ Hz, 1H), 3.50 (s, 3H), 2.98 – 2.86 (m, 4H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 206.5, 141.2, 138.6, 138.3, 137.9, 128.5$ (3), 128.3, 128.0, 127.9, 127.8, 126.1, 101.1, 77.7, 75.5, 74.3, 73.9, 73.7, 73.2, 72.3, 57.9, 40.9, 29.4; HRMS (ESI) m/z calcd for $C_{36}H_{38}O_6Na$ $[M + Na]^+$ 589.2566, found 589.2560.



12t

(*R*)-2-Phenyl-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)propan-1-one (12t).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl (*R*)-2-phenylpropanethioate (24.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 8:1) **12t** (47.7 mg, 84%) as a colorless oil: $[\alpha]_D^{20} = +11.5$ ($c = 2.09$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.35 – 7.13 (m, 20H), 4.82 (d, $J = 12.4$ Hz, 1H), 4.61 (s, 1H), 4.56 (d, $J = 12.1$ Hz, 1H), 4.44 (d, $J = 12.4$ Hz, 1H), 4.41 – 4.37 (m, 2H), 4.32 – 4.28 (m, 1H), 4.00 (s, 2H), 3.84 (d, $J = 9.6$ Hz, 1H), 3.62 (s, 1H), 3.55 (d, $J = 4.4$ Hz, 1H), 3.37 (s, 3H), 1.44 (d, $J = 6.9$ Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 206.9, 140.0, 138.7, 138.1, 137.9, 128.8, 128.7, 128.5, 128.4$ (2), 128.0, 127.9 (2), 127.8, 127.7, 127.1, 100.5, 76.2, 75.5, 75.0, 73.9, 73.8, 73.1, 72.0, 57.4, 50.0, 18.2; HRMS (ESI) m/z calcd for $C_{36}H_{38}O_6Na$ $[M + Na]^+$ 589.2566, found 589.2559.



12u

(2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-Tris(benzyloxy)-6-methoxy-*N,N*-diphenyltetrahydro-2*H*-pyran-2-carboxamide (12u).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-(*p*-tolyl)diphenylcarbamothioate (31.9 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12u** (23.6 mg, 37%) as a colorless oil: $[\alpha]_D^{20} = +49.7$ ($c = 0.97$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.43 – 7.19 (m, 23H), 7.11 – 7.10 (m, 2H), 4.77 (d, $J = 12.6$ Hz, 1H), 4.69 (d, $J = 11.4$ Hz, 1H), 4.60 – 4.54 (m, 2H), 4.46 – 4.41 (m, 3H), 4.36 (d, $J = 12.0$ Hz, 1H), 4.33 (s, 1H), 3.67 (s, 1H), 3.47 – 3.45 (m, 4H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 167.9, 142.9, 142.3, 138.7$ (2), 138.4, 129.4, 129.0, 128.5 (2), 128.4, 127.8 (2), 127.7, 127.6 (2), 126.3, 101.0, 75.6, 74.7, 74.6, 73.6, 73.2 (2), 70.8, 57.8; HRMS (ESI) m/z calcd for C₄₀H₃₉NO₆Na [M + Na]⁺ 652.2675, found 652.2670.



12v

2-(2-Oxo-2-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethyl)isoindoline-1,3-dione (12v).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 2-(1,3-dioxoisindolin-2-yl)ethanethioate³ (29.7 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12v** (51.5 mg, 83%) as a colorless oil: $[\alpha]_D^{20} = +75.7$ ($c = 2.36$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.89 – 7.85 (m, 2H), 7.75 – 7.71 (m, 2H), 7.37 – 7.21 (m, 15H), 4.90 (d, $J = 18.5$ Hz, 1H), 4.83 – 4.79 (m, 2H), 4.73 (d, $J = 12.4$ Hz, 1H), 4.65 – 4.61 (m, 2H), 4.55 – 4.48 (m, 3H), 4.44 (d, $J = 11.6$ Hz, 1H), 4.14 (dd, $J = 8.4, 2.7$ Hz, 1H), 3.73 (dd, $J = 5.2, 2.8$ Hz, 1H), 3.67 (dd, $J = 5.4, 1.7$ Hz, 1H), 3.62 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 199.6, 167.8, 138.3, 138.2, 137.9, 134.1, 132.3, 128.5$ (3), 127.9 (2), 127.8, 123.5, 100.8, 77.3, 75.4, 74.7, 73.8, 73.7, 73.4, 73.1, 58.1, 44.7; HRMS (ESI) m/z calcd for C₃₇H₃₅NO₈Na [M + Na]⁺ 644.2260, found 644.2253.



12w

2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1*H*-indol-3-yl)-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-one (12w).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1*H*-indol-3-yl)ethanethioate⁴ (45.0 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12w** (57.1 mg, 74%) as a yellow solid: $[\alpha]_D^{20} = +43.6$ (*c* = 2.03, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.64 (d, *J* = 8.2 Hz, 2H), 7.45 (d, *J* = 8.1 Hz, 2H), 7.36 – 7.19 (m, 15H), 6.96 (s, 1H), 6.91 (d, *J* = 9.0 Hz, 1H), 6.68 (d, *J* = 8.9 Hz, 1H), 4.83 – 4.77 (m, 2H), 4.63 – 4.59 (m, 2H), 4.52 (d, *J* = 11.9 Hz, 1H), 4.43 – 4.37 (m, 3H), 4.10 (d, *J* = 7.7 Hz, 1H), 4.05 (d, *J* = 15.9 Hz, 1H), 3.87 (d, *J* = 16.0 Hz, 1H), 3.81 – 3.73 (m, 5H), 3.59 (s, 3H), 2.34 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 203.5, 168.3, 156.2, 139.2, 138.5, 138.2, 137.9, 136.3, 134.0, 131.2, 130.9, 129.2, 128.5 (2), 128.4, 128.1, 127.9 (3), 115.0, 112.4, 111.8, 101.5, 101.3, 76.8, 75.5, 74.3, 73.9, 73.8, 73.2, 72.5, 58.1, 55.7, 35.3, 13.7; HRMS (ESI) *m/z* calcd for C₄₆H₄₄NO₈ClNa [M + Na]⁺ 796.2653, found 796.2649.




12x

***N,N*-Dipropyl-4-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbonyl)benzenesulfonamide (12x)**

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-((*N,N*-dipropylsulfamoyl)benzothioate)^{5, 6} (37.8 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12x** (63.6 mg, 91%) as a colorless oil: $[\alpha]_D^{20} = +16.3$ (*c* = 3.45, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.12 (d, *J* = 8.1 Hz, 2H), 7.87 (d, *J* = 8.1 Hz, 2H), 7.39 – 7.29 (m, 15H), 4.96 (d, *J* = 4.8 Hz, 1H, H-5), 4.75 – 4.70 (m, 6H), 4.60 (d, *J* = 11.8 Hz, 1H), 4.48 – 4.45 (m, 1H), 4.04 (d, *J* = 7.8 Hz, 1H), 3.92 (d, *J* = 7.9 Hz, 1H), 3.10 (t, *J* = 7.7 Hz, 4H), 2.93 (s, 3H), 1.57 – 1.50 (m, 4H), 0.86 (t, *J* = 7.4 Hz, 6H); ¹³C NMR (126 MHz, CDCl₃) δ = 195.8, 144.1, 138.5, 138.1, 138.0, 129.9,


128.5, 128.1, 128.0, 127.9 (2), 127.8 (2), 127.1, 101.8, 75.9, 75.7, 75.0, 73.9 (2), 73.4, 73.2, 57.9, 49.8, 21.9, 11.2; HRMS (ESI) m/z calcd for $C_{40}H_{47}NO_8SNa$ $[M + Na]^+$ 724.2920, found 724.2912.



12y

2-(2-Oxo-2-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethyl)dibenzo[*b,e*]oxepin-11(6*H*)-one (12y).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 2-(11-oxo-6,11-dihydrodibenzo[*b,e*]oxepin-2-yl)ethanethioate⁴ (36.0 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12y** (50.3 mg, 73%) as a pale yellow oil: $[\alpha]_D^{20} = +53.6$ ($c = 1.85$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.06 (s, 1H), 7.88 (d, $J = 7.7$ Hz, 1H), 7.55 (t, $J = 7.4$ Hz, 1H), 7.47 (t, $J = 7.5$ Hz, 1H), 7.37 – 7.25 (m, 17H), 7.01 (d, $J = 8.4$ Hz, 1H), 5.17 (s, 2H), 4.82 – 4.77 (m, 2H), 4.61 (t, $J = 13.1$ Hz, 2H), 4.53 (d, $J = 11.9$ Hz, 1H), 4.47 (d, $J = 11.7$ Hz, 1H), 4.44 (d, $J = 11.7$ Hz, 1H), 4.35 (d, $J = 7.6$ Hz, 1H, H-5), 4.12 (dd, $J = 7.6, 2.4$ Hz, 1H), 3.98 (d, $J = 16.7$ Hz, 1H), 3.88 (d, $J = 16.7$ Hz, 1H), 3.80 (dd, $J = 5.5, 2.5$ Hz, 1H), 3.73 (d, $J = 5.9$ Hz, 1H), 3.59 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 204.4, 190.9, 160.4, 140.6, 138.5, 138.2, 137.9, 137.0, 135.6, 132.9, 132.8, 129.5, 129.3, 128.5$ (3), 128.3, 128.0, 127.9 (2), 127.8 (2), 127.7, 125.2, 121.0, 101.2, 77.2, 75.5, 74.3, 73.9, 73.7, 73.6, 73.2, 72.5, 58.2, 44.7; HRMS (ESI) m/z calcd for $C_{43}H_{40}O_8Na$ $[M + Na]^+$ 707.2621, found 707.2610.




12z

(*S*)-2-(6-Methoxynaphthalen-2-yl)-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)propan-1-one (12z).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl (*S*)-2-(6-methoxynaphthalen-2-yl)propanethioate^{5, 6} (32.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 2:1) **12z** (60.2 mg, 93%) as a white solid: $[\alpha]_D^{20} = +154$ ($c = 2.41$, CHCl₃); ¹H


NMR (500 MHz, CDCl₃) δ 7.71 – 7.66 (m, 2H), 7.61 (s, 1H), 7.38 – 7.26 (m, 11H), 7.19 – 7.12 (m, 7H), 4.76 (d, J = 2.4 Hz, 1H), 4.73 (s, 2H), 4.64 (d, J = 11.8 Hz, 1H), 4.61 – 4.48 (m, 4H), 4.22 (dd, J = 5.2, 2.9 Hz, 1H), 4.18 (d, J = 5.3 Hz, 1H, H-5), 3.94 – 3.90 (m, 4H), 3.83 (dd, J = 7.7, 2.3 Hz, 1H), 3.58 (s, 3H), 1.49 (d, J = 6.9 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 207.5, 157.8, 138.7, 138.5, 138.1, 135.5, 133.8, 129.4, 129.2, 128.5, 128.4, 128.3, 128.0 (2), 127.8 (2), 127.6 (2), 126.8, 126.6, 119.1, 105.7, 101.8, 75.9, 75.2, 75.0, 73.9, 73.4, 73.1, 73.0, 58.5, 55.4, 47.9, 17.2; HRMS (ESI) m/z calcd for C₄₁H₄₂O₇Na [M + Na]⁺ 669.2828, found 669.2819.



12aa

(6-(3-(Adamantan-1-yl)-4-methoxyphenyl)naphthalen-2-yl)((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)methanone (12aa).

According to the general protocol A, tributyl((2S,3R,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 6-(3-(adamantan-1-yl)-4-methoxyphenyl)naphthalene-2-carbothioate⁷ (50.5 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 8:1) **12aa** (81.2 mg, 98%) as a pale yellow solid: $[\alpha]_D^{20}$ = +25.0 (c = 3.71, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.60 (s, 1H), 8.09 (dd, J = 8.7, 1.7 Hz, 1H), 8.01 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 8.7 Hz, 1H), 7.80 (dd, J = 8.6, 1.8 Hz, 1H), 7.62 (d, J = 2.1 Hz, 1H), 7.56 (dd, J = 8.4, 2.3 Hz, 1H), 7.44 – 7.27 (m, 14H), 7.23 (s, 1H), 7.00 (d, J = 8.5 Hz, 1H), 5.18 (d, J = 4.3 Hz, 1H, H-5), 4.81 – 4.78 (m, 5H), 4.74 (d, J = 12.2 Hz, 1H), 4.69 (d, J = 11.9 Hz, 1H), 4.60 (t, J = 3.7 Hz, 1H), 4.20 (dd, J = 8.4, 2.7 Hz, 1H), 4.01 (dd, J = 8.4, 2.6 Hz, 1H), 3.90 (s, 3H), 2.89 (s, 3H), 2.21 (s, 6H), 2.13 (s, 3H), 1.83 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ = 196.9, 159.0, 141.8, 139.1, 138.8 (2), 138.4, 136.0, 132.6, 132.4, 131.2 (2), 130.2, 128.5, 128.4 (3), 128.1, 128.0, 127.9, 127.7 (3), 126.6, 126.1, 125.8, 125.2, 124.8, 112.2, 101.8, 77.4, 76.0, 75.8, 75.6, 74.5, 73.8, 73.4, 73.3, 57.9, 55.2, 40.7, 37.3, 37.2, 29.2; HRMS (ESI) m/z calcd for C₅₅H₅₆O₇Na [M + Na]⁺ 851.3924, found 851.3915.




12ab

1-([1,1'-Biphenyl]-4-yl)-4-((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)butane-1,4-dione (12ab).

According to the general protocol A, tributyl((2S,3R,4R,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-([1,1'-biphenyl]-4-yl)-4-oxobutanethioate **S5** (34.6 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under


Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12ab** (55.7 mg, 83%) as a pale yellow solid: $[\alpha]_D^{20} = +51.9$ (c = 2.21, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.08 (d, *J* = 8.1 Hz, 2H), 7.70 (d, *J* = 8.1 Hz, 2H), 7.65 (d, *J* = 7.7 Hz, 2H), 7.51 – 7.48 (m, 2H), 7.43 – 7.28 (m, 16H), 4.83 – 4.79 (m, 2H), 4.68 – 4.53 (m, 5H), 4.46 (d, *J* = 7.6 Hz, 1H, H-5), 4.21 (dd, *J* = 7.5, 2.1 Hz, 1H), 3.84 (dd, *J* = 5.4, 2.2 Hz, 1H), 3.76 (d, *J* = 5.8 Hz, 1H), 3.57 (s, 3H), 3.38 – 3.27 (m, 2H), 3.21 – 3.07 (m, 2H); ¹³C NMR (126 MHz, CDCl₃) δ = 206.4, 198.1, 145.8, 140.0, 138.6, 138.3, 138.1, 135.5, 129.0, 128.7, 128.5, 128.4, 128.3 (2), 127.9 (2), 127.8 (3), 127.3 (2), 101.1, 77.9, 75.6, 74.5, 73.9, 73.8, 73.2, 72.5, 57.9, 33.3, 32.3; HRMS (ESI) *m/z* calcd for C₄₃H₄₂O₇Na [M + Na]⁺ 693.2828, found 693.2821.



12ac

(*S*)-2-(4-Isobutylphenyl)-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)propan-1-one (12ac).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl (*S*)-2-(4-isobutylphenyl)propanethioate **S6** (29.8 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 8:1) **12ac** (60.8 mg, 98%) as a colorless oil: $[\alpha]_D^{20} = +134$ (c = 1.60, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.32 – 7.23 (m, 13H), 7.19 – 7.17 (m, 2H), 7.10 (d, *J* = 8.1 Hz, 2H), 7.06 (d, *J* = 8.1 Hz, 2H), 4.70 (dd, *J* = 11.2, 2.4 Hz, 3H), 4.63 – 4.49 (m, 4H), 4.36 – 4.31 (m, 1H), 4.19 – 4.16 (m, 2H), 3.86 (dd, *J* = 7.6, 2.1 Hz, 1H), 3.78 (dd, *J* = 7.6, 2.5 Hz, 1H), 3.52 (s, 3H), 2.44 (d, *J* = 7.2 Hz, 2H), 1.88 – 1.80 (m, 1H), 1.37 (d, *J* = 7.0 Hz, 3H), 0.90 – 0.89 (m, 6H); ¹³C NMR (126 MHz, CDCl₃) δ = 207.6, 140.7, 138.7, 138.6, 138.3, 137.6, 129.8, 128.5, 128.4 (2), 128.1, 128.0, 127.9, 127.8 (2), 127.7 (2), 101.8, 75.9, 75.2 (2), 73.9, 73.4, 73.2, 72.9, 58.4, 47.7, 45.1, 30.3, 22.5 (2), 17.2; HRMS (ESI) *m/z* calcd for C₄₀H₄₆O₆Na [M + Na]⁺ 645.3192, found 645.3189.




12ad

(*S*)-2-(3-benzoylphenyl)-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)propan-1-one (12ad).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl (*S*)-2-(3-benzoylphenyl)propanethioate **S7** (34.6 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated


under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **12ad** (59.9 mg, 89%) as a colorless oil: $[\alpha]_D^{20} = +110$ (c = 2.23, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.79 (d, *J* = 7.5 Hz, 2H), 7.73 (s, 1H), 7.69 (d, *J* = 7.3 Hz, 1H), 7.59 (t, *J* = 7.3 Hz, 1H), 7.49 – 7.40 (m, 4H), 7.35 – 7.23 (m, 15H), 4.73 (d, *J* = 12.8 Hz, 2H), 4.66 – 4.62 (m, 2H), 4.57 – 4.45 (m, 4H), 4.18 (s, 2H), 3.83 (d, *J* = 6.7 Hz, 1H), 3.76 (d, *J* = 6.7 Hz, 1H), 3.52 (s, 3H), 1.44 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 206.7, 196.4, 140.7, 138.5, 138.4, 138.2, 138.1, 137.5, 132.6, 132.0, 130.1, 129.9, 129.0, 128.9, 128.4 (4), 128.1, 127.9, 127.8 (3), 127.7, 101.6, 75.7, 75.4, 74.8, 73.9, 73.4, 73.2, 72.9, 58.3, 47.9, 17.3; HRMS (ESI) *m/z* calcd for C₄₃H₄₂O₇Na [M + Na]⁺ 693.2828, found 693.2823.



12ae

2-(3-ethoxy-4-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbonyl)phenyl)-*N*-((*S*)-3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)acetamide (12ae**).**


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl (*S*)-2-ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzothioate⁷ (54.5 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 2:1) **12ae** (80.4 mg, 93%) as a yellow oil: $[\alpha]_D^{20} = +4.93$ (c = 2.56, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.61 (d, *J* = 7.8 Hz, 1H), 7.39 – 7.19 (m, 17H), 7.07 – 7.03 (m, 2H), 6.87 (d, *J* = 7.9 Hz, 1H), 6.83 (s, 1H), 6.71 (d, *J* = 8.1 Hz, 1H), 5.42 – 5.37 (m, 1H), 5.26 (d, *J* = 4.2 Hz, 1H, H-5), 4.76 – 4.66 (m, 6H), 4.63 (d, *J* = 2.4 Hz, 1H), 4.52 – 4.51 (m, 1H), 4.08 – 3.91 (m, 4H), 3.52 (s, 2H), 2.98 – 2.92 (m, 2H), 2.84 (s, 3H), 2.64 – 2.61 (m, 2H), 1.77 – 1.71 (m, 2H), 1.68 – 1.37 (m, 10H), 0.92 (d, *J* = 6.5 Hz, 6H); ¹³C NMR (126 MHz, CDCl₃) δ = 199.2, 168.8, 158.2, 152.6, 141.4, 138.9, 138.8, 138.7, 138.6, 132.2, 128.4, 128.0 (2), 127.8, 127.7, 127.6, 127.5, 126.2, 125.1, 122.8, 121.4, 113.0, 101.7, 78.0, 75.9, 75.4, 74.6, 73.8, 73.1, 73.0, 64.4, 57.7, 49.7, 46.7, 44.3, 26.8, 25.4, 24.2, 22.8, 22.6, 14.7; HRMS (ESI) *m/z* calcd for C₅₄H₆₅N₂O₈ [M + H]⁺ 869.4741, found 869.4734.



12af

((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methyl 4-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbonyl)benzoate (12af**)**


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), ((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methyl 4-((phenylthio)carbonyl)benzoate **S10** (70.5 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 3:1) **12af** (81.6 mg, 79%) as a colorless oil: $[\alpha]_D^{20} = +42.4$ (c = 3.62, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.04 (s, 4H), 7.38 – 7.19 (m, 30H), 5.03 (d, *J* = 10.7 Hz, 1H), 4.97 (d, *J* = 4.6 Hz, 1H), 4.92 (d, *J* = 10.9 Hz, 1H), 4.85 (d, *J* = 10.7 Hz, 1H), 4.82 (d, *J* = 12.1 Hz, 1H), 4.75 – 4.67 (m, 7H), 4.63 – 4.61 (m, 3H), 4.54 (dd, *J* = 12.0, 2.2 Hz, 1H), 4.50 – 4.46 (m, 2H), 4.08 – 4.05 (m, 2H), 3.97 – 3.92 (m, 2H), 3.61 – 3.57 (m, 2H), 3.39 (s, 3H), 2.89 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 196.4, 165.4, 138.9, 138.6 (2), 138.5, 138.2, 138.1, 137.8, 133.4, 129.7, 129.2, 128.6 (3), 128.4 (2), 128.2 (2), 128.1 (2), 128.0, 127.9 (3), 127.8 (2), 127.7, 101.8, 98.1, 82.2, 80.1, 77.5, 76.0, 75.8, 75.7, 75.3, 75.1, 74.1, 73.8, 73.5, 73.4, 73.3, 68.7, 64.0, 58.0, 55.3; HRMS (ESI) *m/z* calcd for C₆₃H₆₄O₁₃Na [M + Na]⁺ 1051.4245, found 1051.4252.



9e'

Tributyl((2*S*,3*S*,4*R*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane (**9e'**)

A solution of (2*S*,3*S*,4*S*,5*R*,6*R*)-4,5-bis(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2*H*-pyran-3-ol¹ (311 mg, 0.491 mmol) in anh. THF (3.00 mL) was cooled to 0 °C, and a solution of KHMDS (0.983 mL, 0.983 mmol, 1.0 M in THF) was added at 0 °C. After stirring for 0.5 h, BnBr (0.117 mL, 0.983 mmol) was added, and the reaction mixture was stirred at 0 °C for additional 0.5 h and then at rt overnight. The resulting solution was concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 20:1) to afford **9e'** (262 mg, 74%) as a colorless oil: $[\alpha]_D^{20} = -38.9$ (c = 0.95, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.27 (m, 15H), 4.96 (d, *J* = 10.9 Hz, 1H), 4.83 (t, *J* = 11.9 Hz, 2H), 4.71 (t, *J* = 11.8 Hz, 2H), 4.58 (d, *J* = 11.4 Hz, 1H), 4.48 (d, *J* = 6.1 Hz, 1H, H-5), 4.41 (d, *J* = 6.1 Hz, 1H), 3.81 (t, *J* = 6.6 Hz, 1H), 3.71 (dd, *J* = 9.3, 7.4 Hz, 1H), 3.47 – 3.44 (m, 4H), 1.49 – 1.43 (m, 6H), 1.31 – 1.23 (m, 6H), 0.92 – 0.82 (m, 15H); ¹³C NMR (126 MHz, CDCl₃) δ = 138.9, 138.7, 138.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.7, 127.6 (2), 105.5, 83.3, 82.5, 82.2, 75.1, 74.1, 73.2, 70.8, 55.9, 29.2, 27.6, 13.8, 10.4; HRMS (ESI) *m/z* calcd for C₃₉H₅₆O₅SnNa [M + Na]⁺ 747.3047, found 747.3062.




9f

Tributyl((2*R*,3*S*,4*R*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane (**9f**)

A solution of (2*R*,3*S*,4*S*,5*S*,6*S*)-4,5-bis(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2*H*-pyran-3-ol¹ (506 mg, 0.799 mmol) in anh. THF (5.00 mL) was cooled to 0 °C, and a solution of KHMDS (1.60 mL, 1.60 mmol, 1.0 M in THF) was added at 0 °C. After stirring for 0.5 h, BnBr (0.200 mL, 1.60 mmol) was added, and the reaction mixture was stirred at 0 °C for additional 0.5


h and then at rt overnight. The resulting solution was concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 20:1) to afford **9f** (546 mg, 94%) as a colorless oil: $[\alpha]_D^{20} = +19.3$ ($c = 1.02$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.40 – 7.39 (m, 2H), 7.34 – 7.26 (m, 13H), 5.10 (d, $J = 11.1$ Hz, 1H), 4.76 (d, $J = 12.4$ Hz, 1H), 4.71 (d, $J = 12.4$ Hz, 1H), 4.67 (s, 1H), 4.63 – 4.61 (m, 2H), 4.57 (d, $J = 11.6$ Hz, 1H), 4.14 – 4.10 (m, 1H), 3.85 – 3.82 (m, 3H), 3.30 (s, 3H), 1.56 – 1.45 (m, $J = 7.5$ Hz, 6H), 1.32 – 1.25 (m, 6H), 1.01 – 0.85 (m, 15H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 139.1, 138.8, 138.6, 128.5, 128.4, 128.3, 127.9, 127.8, 127.7, 127.6$ (2), 127.4, 100.0, 82.5, 77.6, 75.2, 74.4, 72.7, 71.8, 65.1, 54.7, 29.3, 27.6, 13.8, 9.2; HRMS (ESI) m/z calcd for C₃₉H₅₆O₅SnNa [M + Na]⁺ 747.3042, found 747.3040.



9h

((2*S*,3*R*,5*R*,6*S*)-3,5-Bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)tributylstannane (9h**).**

A solution of (2*S*,3*R*,5*R*,6*S*)-5-(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2*H*-pyran-3-ol¹ (611 mg, 1.16 mmol) in anh. THF (7.20 mL) was cooled to 0 °C, and a solution of KHMDS (2.30 mL, 2.30 mmol, 1.0 M in THF) was added at 0 °C. After stirring for 0.5 h, BnBr (0.300 mL, 2.53 mmol) was added, and the reaction mixture was stirred at 0 °C for additional 0.5 h and then at rt overnight. The resulting solution was concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 20:1) to afford **9h** (590 mg, 83%) as a colorless oil: $[\alpha]_D^{20} = -2.29$ ($c = 0.88$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.40 – 7.25 (m, 10H), 4.77 (d, $J = 12.7$ Hz, 1H), 4.60 (d, $J = 12.7$ Hz, 1H), 4.43 (d, $J = 11.6$ Hz, 1H), 4.37 – 4.34 (m, 2H), 3.88 – 3.84 (m, 1H), 3.80 – 3.76 (m, 2H), 3.50 (s, 3H), 2.33 – 2.29 (m, 1H), 1.58 – 1.44 (m, 7H), 1.32 – 1.25 (m, 6H), 0.96 – 0.84 (m, 15H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 139.3, 138.6, 128.4$ (2), 127.9, 127.8, 127.6 (2), 104.0, 74.8, 73.7, 72.6, 72.3, 70.5, 57.3, 33.1, 29.3, 27.6, 13.8, 9.4; HRMS (ESI) m/z calcd for C₃₂H₅₀O₄SnNa [M + Na]⁺ 641.2629, found 641.2628.




9i

((2*R*,3*S*,4*R*,6*R*)-3,4-bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)tributylstannane (9i**).**


A solution of (2*R*,3*S*,4*R*,6*R*)-4-(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2*H*-pyran-3-ol¹ (171 mg, 0.324 mmol) in anh. THF (2.00 mL) was cooled to 0 °C, and a solution of KHMDS (0.650 mL, 0.650 mmol, 1.0 M in THF) was added at 0 °C. After stirring for 0.5 h, BnBr (0.100 mL, 0.842 mmol) was added, and the reaction mixture was stirred at 0 °C for additional 0.5 h and then at rt overnight. The resulting solution was concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 30:1) to afford **9i** (196 mg, 98%) as a colorless oil: $[\alpha]_D^{20} = -11.5$ ($c = 1.47$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.32 – 7.27 (m, 10H), 5.13 (d, $J = 11.1$ Hz, 1H), 4.65 (d, $J = 11.4$ Hz, 1H), 4.61 (d, $J = 11.1$ Hz, 1H), 4.53 (d, $J = 11.4$ Hz, 1H), 4.17 (d, $J = 9.5$ Hz, 1H), 3.67 – 3.59 (m, 2H), 3.46 – 3.41 (m, 4H), 2.36 (dd, $J = 12.2, 4.1$ Hz, 1H), 1.55 – 1.43 (m, 7H), 1.30 – 1.23 (m, 6H), 0.96 – 0.84 (m, 15H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 138.9, 138.4, 128.6, 128.3, 128.0, 127.8$ (2), 127.5, 103.9, 81.8, 81.0, 74.5, 71.0, 69.4, 56.6, 36.6,

29.2, 27.6, 13.8, 9.2; HRMS (ESI) m/z calcd for $C_{32}H_{50}O_4SnNa$ $[M + Na]^+$ 641.2629, found 641.2625.




(2*R*,3*R*,4*R*,5*S*,6*R*)-*N,N*-Dibenzyl-4,5-bis(benzyloxy)-2-methoxy-6-(tributylstannyl)tetrahydro-2*H*-pyran-3-amine (9j).

A solution of (2*R*,3*S*,4*R*,5*R*,6*R*)-4-(benzyloxy)-5-(dibenzylamino)-6-methoxy-2-(tributylstannyl)tetrahydro-2*H*-pyran-3-ol¹ (511 mg, 0.707 mmol) in anh. THF (4.40 mL) was cooled to 0 °C, and a solution of KHMDS (1.40 mL, 1.40 mmol, 1.0 M in THF) was added at 0 °C. After stirring for 0.5 h, BnBr (0.200 mL, 1.68 mmol) was added, and the reaction mixture was stirred at 0 °C for additional 0.5 h and then at rt overnight. The resulting solution was concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 40:1) to afford **9j** (557 mg, 97%) as a colorless oil: $[\alpha]_D^{20} = -13.9$ ($c = 2.81$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.44 – 7.21 (m, 20H), 5.14 (d, $J = 11.1$ Hz, 1H), 4.96 (d, $J = 11.1$ Hz, 1H), 4.82 (d, $J = 11.1$ Hz, 1H), 4.60 – 4.56 (m, 1H), 4.36 (d, $J = 8.4$ Hz, 1H), 4.09 (d, $J = 13.8$ Hz, 2H), 3.93 (d, $J = 13.8$ Hz, 2H), 3.74 – 3.66 (m, 2H), 3.59 (s, 3H), 3.46 (d, $J = 10.8$ Hz, 1H, H-5), 2.92 (t, $J = 9.0$ Hz, 1H), 1.54 – 1.44 (m, 6H), 1.33 – 1.25 (m, 6H), 0.99 – 0.87 (m, 15H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 140.1, 139.2, 138.6, 129.0, 128.5, 128.3$ (2), 128.2, 127.9, 127.8, 127.5, 127.4, 127.3, 126.8, 106.7, 83.8, 82.6, 74.4, 74.2, 72.3, 69.0, 63.7, 56.3, 55.2, 29.2, 27.6, 13.8, 9.2; HRMS (ESI) m/z calcd for $C_{46}H_{64}NO_4Sn$ $[M + H]^+$ 814.3857, found 814.3864.



Tributyl((2*S*,3*R*,4*S*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane (9i).


A solution of (2*S*,3*R*,4*R*,5*S*,6*S*)-4,5-bis(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2*H*-pyran-3-ol **S8** (1.00 g, 1.58 mmol) in anh. THF (9.90 mL) was cooled to 0 °C, and a solution of KHMDS (3.20 mL, 3.20 mmol, 1.0 M in THF) was added at 0 °C. After stirring for 0.5 h, BnBr (0.400 mL, 3.37 mmol) was added, and the reaction mixture was stirred at 0 °C for additional 0.5 h and then at rt overnight. The resulting solution was concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 30:1) to afford **9i** (1.02 g, 89%) as a colorless oil: $[\alpha]_D^{20} = -8.75$ ($c = 0.82$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.24 (m, 15H), 5.05 (d, $J = 11.0$ Hz, 1H), 4.97 – 4.93 (m, 2H), 4.75 – 4.69 (m, 2H), 4.60 (d, $J = 10.8$ Hz, 1H), 4.14 (d, $J = 7.1$ Hz, 1H), 3.71 (t, $J = 9.8$ Hz, 1H), 3.59 (t, $J = 8.2$ Hz, 1H), 3.55 (s, 3H), 3.47 (d, $J = 10.5$ Hz, 1H, H-5), 3.41 (t, $J = 8.0$ Hz, 1H), 1.53 – 1.41 (m, 6H), 1.31 – 1.23 (m, 6H), 0.99 – 0.85 (m, 15H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 138.9, 138.7, 138.6, 128.5$ (2), 128.4, 128.2, 128.1, 127.7, 127.6 (2), 107.9, 87.1, 83.1, 81.1, 75.6, 74.9, 74.4, 69.1, 57.0, 29.2, 27.6, 13.8, 9.2; HRMS (ESI) m/z calcd for $C_{39}H_{56}O_5SnNa$ $[M + Na]^+$ 747.3047, found 747.3050.



13a

((2*R*,3*R*,4*S*,5*R*,6*S*)-4,5-Bis(benzyloxy)-3-hydroxy-6-methoxytetrahydro-2*H*-pyran-2-yl)(4-methoxyphenyl)methanone (13a).


According to the general protocol A, (2*S*,3*R*,4*S*,5*R*,6*S*)-4,5-bis(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2*H*-pyran-3-ol¹ (127 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 2:1) **13a** (29.5 mg, 62%) as a colorless oil: $[\alpha]_D^{20} = +7.99$ ($c = 1.41$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, $J = 8.6$ Hz, 2H), 7.39 – 7.27 (m, 10H), 6.93 (d, $J = 8.6$ Hz, 2H), 4.93 (d, $J = 4.3$ Hz, 1H, H-5), 4.77 – 4.67 (m, 6H), 4.13 (dd, $J = 7.8, 3.0$ Hz, 1H), 3.86 (s, 3H), 3.83 (dd, $J = 7.9, 2.4$ Hz, 1H), 2.98 (s, 3H), 2.86 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 196.1, 163.6, 138.5, 138.3, 131.8, 128.6, 128.5, 128.4, 128.0$ (2), 127.9, 113.7, 101.6, 76.1, 75.4, 73.7, 73.5, 67.2, 57.9, 55.5; HRMS (ESI) m/z calcd for C₂₈H₃₀O₇Na [M + Na]⁺ 501.1889, found 501.1884.



13b

((2*S*,3*R*,4*S*,5*R*,6*R*)-5-(Benzyloxy)-3-hydroxy-6-methoxy-4-(triisopropylsilyloxy)tetrahydro-2*H*-pyran-2-yl)(4-methoxyphenyl)methanone (13b).


According to the general protocol A, (2*R*,3*S*,4*S*,5*R*,6*R*)-5-(benzyloxy)-6-methoxy-2-(tributylstannyl)-4-(triisopropylsilyloxy)tetrahydro-2*H*-pyran-3-ol¹ (140 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 8:1) **13b** (28.9 mg, 53%) as a colorless oil: $[\alpha]_D^{20} = +15.3$ ($c = 1.37$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.98 (d, $J = 8.9$ Hz, 2H), 7.36 – 7.27 (m, 5H), 6.95 (d, $J = 8.9$ Hz, 2H), 4.93 (d, $J = 11.2$ Hz, 1H), 4.68 (d, $J = 11.2$ Hz, 1H), 4.51 (d, $J = 7.7$ Hz, 1H), 4.36 (d, $J = 9.2$ Hz, 1H, H-5), 4.00 (t, $J = 9.0$ Hz, 1H), 3.93 (t, $J = 8.6$ Hz, 1H), 3.88 (s, 3H), 3.48 (s, 3H), 3.32 (t, $J = 8.1$ Hz, 1H), 2.82 (s, 1H), 1.19 – 1.15 (m, 3H), 1.09 – 1.07 (m, 18H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 194.7, 164.2, 139.1, 131.9, 128.4, 128.2, 127.7, 127.4, 113.9, 105.8, 82.6, 76.9, 75.4, 74.5, 72.1, 57.3, 55.6, 18.4$ (2), 13.1; HRMS (ESI) m/z calcd for C₃₀H₄₄O₇SiNa [M + Na]⁺ 567.2754, found 567.2748.



13c

(4-Methoxyphenyl)((2*S*,3*S*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (13c).


According to the general protocol A, tributyl((2*R*,3*S*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **13c** (12.5 mg, 22%) as a colorless oil: $[\alpha]_D^{20} = -2.87$ (c = 0.67, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, *J* = 8.6 Hz, 2H), 7.37 – 7.28 (m, 10H), 7.19 – 7.13 (m, 3H), 6.93 – 6.90 (m, 4H), 5.08 (d, *J* = 9.7 Hz, 1H, H-5), 4.99 (d, *J* = 10.9 Hz, 1H), 4.87 – 4.82 (m, 2H), 4.70 – 4.65 (m, 3H), 4.41 (d, *J* = 10.4 Hz, 1H), 4.11 (t, *J* = 9.3 Hz, 1H), 3.92 – 3.87 (m, 4H), 3.64 (dd, *J* = 9.7, 3.4 Hz, 1H), 3.47 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 194.6, 164.2, 138.8, 138.2, 137.9, 131.6, 129.5, 128.7, 128.5, 128.3, 128.2 (2), 128.0, 127.8, 127.7, 114.0, 99.5, 81.9, 80.0, 79.6, 76.0, 75.3, 73.8, 69.4, 56.4, 55.7; HRMS (ESI) *m/z* calcd for C₃₅H₃₆O₇Na [M + Na]⁺ 591.2359, found 591.2351.



13d

(4-Methoxyphenyl)((2*S*,3*S*,4*S*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (13d).

According to the general protocol A, tributyl((2*R*,3*S*,4*R*,5*R*,6*R*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **13d** (42.0 mg, 74%) as a white solid: $[\alpha]_D^{20} = -11.5$ (c = 2.17, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.06 (d, *J* = 8.7 Hz, 2H), 7.40 – 7.30 (m, 10H), 7.22 – 7.21 (m, 3H), 7.07 – 7.05 (m, 2H), 6.97 (d, *J* = 8.8 Hz, 2H), 4.99 – 4.95 (m, 2H), 4.87 (d, *J* = 11.0 Hz, 1H), 4.78 – 4.75 (m, 2H), 4.67 (d, *J* = 9.4 Hz, 1H, H-5), 4.63 (d, *J* = 10.4 Hz, 1H), 4.53 (d, *J* = 7.6 Hz, 1H), 4.10 (t, *J* = 9.2 Hz, 1H), 3.89 (s, 3H), 3.83 (t, *J* = 9.1 Hz, 1H), 3.59 – 3.55 (m, 4H); ¹³C NMR (126 MHz, CDCl₃) δ = 192.6, 164.1, 138.6, 138.5, 138.0, 131.6, 129.0, 128.5, 128.3, 128.2, 127.9, 127.8, 127.7, 113.9, 105.4, 84.5, 82.0, 79.0, 75.9, 75.1, 74.9, 74.7, 57.3, 55.6; HRMS (ESI) *m/z* calcd for C₃₅H₃₆O₇Na [M + Na]⁺ 591.2359, found 591.2355.




13e

(4-Methoxyphenyl)((2*S*,3*S*,4*S*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (13e).


According to the general protocol A, tributyl((2*R*,3*S*,4*R*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane **9f** (145 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **13e** (49.6 mg, 87%) as a white solid: $[\alpha]_D^{20} = +27.2$ (c = 1.90, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.15

(d, $J = 8.4$ Hz, 2H), 7.44 – 7.30 (m, 10H), 7.23 – 7.20 (m, 3H), 7.11 – 7.09 (m, 2H), 6.87 (d, $J = 8.3$ Hz, 2H), 4.87 – 4.67 (m, 7H), 4.52 – 4.46 (m, 2H), 4.04 (dd, $J = 9.1, 2.3$ Hz, 1H), 3.88 – 3.86 (m, 4H), 3.43 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) $\delta = 194.1, 163.8, 138.6, 138.4, 138.2, 132.0, 128.9, 128.5, 128.2, 128.0, 127.8, 127.7, 127.6, 113.8, 100.2, 79.7, 76.2, 74.9, 73.9, 73.0, 72.5, 55.8, 55.5$; HRMS (ESI) m/z calcd for $\text{C}_{35}\text{H}_{36}\text{O}_7\text{Na}$ $[\text{M} + \text{Na}]^+$ 591.2359, found 591.2354.




((2*S*,3*S*,4*S*,5*R*,6*R*)-5-(Benzyloxy)-6-methoxy-3,4-bis(naphthalen-2-ylmethoxy)tetrahydro-2*H*-pyran-2-yl)(4-methoxyphenyl)methanone (13f).

According to the general protocol A, ((2*R*,3*S*,4*R*,5*R*,6*R*)-5-(benzyloxy)-6-methoxy-3,4-bis(naphthalen-2-ylmethoxy)tetrahydro-2*H*-pyran-2-yl)tributylstannane¹ (165 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), $\text{Pd}_2(\text{dba})_3$ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO_2 (Hexanes:EtOAc, 4:1) **13f** (52.5 mg, 79%) as a white solid: $[\alpha]_D^{20} = -64.5$ ($c = 2.22$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 8.08 (d, $J = 8.9$ Hz, 2H), 7.86 – 7.75 (m, 5H), 7.65 – 7.58 (m, 2H), 7.52 – 7.31 (m, 11H), 7.17 (d, $J = 8.4$ Hz, 1H), 6.93 (d, $J = 8.9$ Hz, 2H), 5.17 (d, $J = 11.3$ Hz, 1H), 5.06 (d, $J = 11.3$ Hz, 1H), 5.01 (d, $J = 11.1$ Hz, 1H), 4.94 (d, $J = 10.7$ Hz, 1H), 4.82 (d, $J = 11.1$ Hz, 1H), 4.78 (d, $J = 10.7$ Hz, 1H), 4.74 (d, $J = 9.5$ Hz, 1H, H-5), 4.58 (d, $J = 7.6$ Hz, 1H), 4.19 (t, $J = 9.2$ Hz, 1H), 3.94 (t, $J = 9.1$ Hz, 1H), 3.84 (s, 3H), 3.68 – 3.65 (m, 1H), 3.58 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) $\delta = 192.8, 164.0, 138.5, 136.1, 135.4, 133.4, 133.2, 133.1, 133.0, 131.7, 128.9, 128.5, 128.2$ (2), 128.0 (2), 127.8 (2), 127.6, 126.9, 126.6, 126.2, 126.1, 126.0, 125.9 (2), 125.8, 113.9, 105.4, 84.5, 82.0, 79.2, 75.9, 75.2, 74.9, 74.8, 57.3, 55.5; HRMS (ESI) m/z calcd for $\text{C}_{43}\text{H}_{40}\text{O}_7\text{Na}$ $[\text{M} + \text{Na}]^+$ 691.2672, found 691.2662.




((2*R*,3*R*,5*R*,6*S*)-3,5-Bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)(4-methoxyphenyl)methanone (13g).

According to the general protocol A, ((2*S*,3*R*,5*R*,6*S*)-3,5-bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)tributylstannane **9h** (123 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), $\text{Pd}_2(\text{dba})_3$ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO_2 (Hexanes:EtOAc, 4:1) **13g** (44.8 mg, 97%) as a colorless oil: $[\alpha]_D^{20} = +39.3$ ($c = 1.76$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 8.04 (d, $J = 8.3$ Hz, 2H), 7.37 – 7.26 (m, 10H), 6.93 (d, $J = 8.3$ Hz, 2H), 4.77 (br, 1H, H-5), 4.62 – 4.51 (m, 5H), 4.41 – 4.39 (m, 1H), 3.92 – 3.89 (m, 1H), 3.86 (s, 3H), 2.88 (s, 3H), 2.30 – 2.24 (m, 1H), 2.08 – 2.03 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3) $\delta = 195.9, 163.3, 138.6, 138.3, 131.7, 128.7, 128.5$ (2), 127.9 (2), 127.8 (2), 113.6, 101.1, 76.0, 72.8, 71.7, 71.5, 71.3, 57.7, 55.5, 26.9; HRMS (ESI) m/z calcd for $\text{C}_{28}\text{H}_{30}\text{O}_6\text{Na}$ $[\text{M} + \text{Na}]^+$ 485.1940, found 485.1937.




((2*S*,3*S*,4*R*,6*R*)-3,4-Bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)(4-methoxyphenyl)methanone (13h**).**

According to the general protocol A, ((2*R*,3*S*,4*R*,6*R*)-3,4-bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)tributylstannane **9i** (61.7 mg, 0.100 mmol), *S*-phenyl 4-methoxybenzothioate (48.9 mg, 0.200 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **13h** (38.2 mg, 83%) as a white solid: $[\alpha]_D^{20} = -19.3$ (*c* = 1.48, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.04 (d, *J* = 8.8 Hz, 2H), 7.41 – 7.29 (m, 5H), 7.24 – 7.19 (m, 3H), 7.13 – 7.09 (m, 2H), 6.94 (d, *J* = 8.8 Hz, 2H), 4.83 (d, *J* = 10.5 Hz, 1H), 4.74 (d, *J* = 11.7 Hz, 1H), 4.68 (d, *J* = 11.7 Hz, 1H), 4.65 (d, *J* = 10.4 Hz, 1H), 4.59 (d, *J* = 9.3 Hz, 1H, H-5), 4.56 (dd, *J* = 9.6, 1.6 Hz, 1H), 4.01 (t, *J* = 9.0 Hz, 1H), 3.88 (s, 3H), 3.85 – 3.80 (m, 1H), 3.46 (s, 3H), 2.41 – 2.38 (m, 1H), 1.79 – 1.72 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ = 192.8, 163.9, 138.4, 138.3, 131.7, 129.1, 128.6, 128.3, 128.2, 127.8 (2), 127.7, 113.9, 101.8, 79.1, 79.0, 75.1, 75.0, 71.8, 56.8, 55.6, 36.4; HRMS (ESI) *m/z* calcd for C₂₈H₃₀O₆Na [M + Na]⁺ 485.1940, found 485.1932.



((2*S*,3*S*,4*R*,5*R*,6*R*)-3,4-Bis(benzyloxy)-5-(dibenzylamino)-6-methoxytetrahydro-2*H*-pyran-2-yl)(4-methoxyphenyl)methanone (13i**).**


According to the general protocol A, (2*R*,3*R*,4*R*,5*S*,6*R*)-*N,N*-dibenzyl-4,5-bis(benzyloxy)-2-methoxy-6-(tributylstannyl)tetrahydro-2*H*-pyran-3-amine **9j** (163 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **13i** (65.1 mg, 99%) as a colorless oil: $[\alpha]_D^{20} = -22.5$ (*c* = 2.79, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.04 (d, *J* = 8.8 Hz, 2H), 7.41 – 7.40 (m, 8H), 7.36 – 7.16 (m, 10H), 7.02 – 7.00 (m, 2H), 6.93 (d, *J* = 8.8 Hz, 2H), 5.02 (d, *J* = 11.2 Hz, 1H), 4.93 (d, *J* = 11.2 Hz, 1H), 4.68 – 4.62 (m, 3H), 4.59 (d, *J* = 10.4 Hz, 1H), 4.14 (t, *J* = 9.0 Hz, 1H), 4.04 (d, *J* = 13.8 Hz, 2H), 3.97 (t, *J* = 9.2 Hz, 1H), 3.86 – 3.83 (m, 5H), 3.40 (s, 3H), 3.09 (dd, *J* = 9.6, 6.8 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) δ = 193.3, 163.9, 139.7, 139.0, 138.1, 131.6, 129.0 (2), 128.4, 128.3 (2), 128.2, 127.7, 127.4, 127.0, 113.9, 103.7, 80.8, 79.4, 75.3, 74.8, 74.4, 63.8, 56.4, 55.6, 55.1; HRMS (ESI) *m/z* calcd for C₄₂H₄₃NO₆Na [M + Na]⁺ 680.2988, found 680.2980.



13j

(4-Methoxyphenyl)((2R,3S,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)methanone (13j)

According to the general protocol A, tributyl((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)stannane **9e'** (145 mg, 0.200 mmol), *S*-phenyl 4-methoxybenzothioate (24.4 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **13j** (8.10 mg, 14%) as a colorless oil: $[a]_D^{20} = -6.5$ ($c = 0.65$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.92 (d, $J = 8.9$ Hz, 2H), 7.35 – 7.27 (m, 10H), 7.20 – 7.13 (m, 3H), 6.99 – 6.97 (m, 2H), 6.89 (d, $J = 8.9$ Hz, 2H), 5.25 (d, $J = 4.8$ Hz, 1H, H-5), 4.87 (d, $J = 5.3$ Hz, 1H), 4.83 (d, $J = 11.3$ Hz, 1H), 4.77 (d, $J = 11.7$ Hz, 1H), 4.67 (dd, $J = 11.5, 3.6$ Hz, 2H), 4.58 (d, $J = 11.8$ Hz, 1H), 4.33 (d, $J = 11.8$ Hz, 1H), 4.09 (dd, $J = 7.6, 6.2$ Hz, 1H), 3.98 (dd, $J = 6.2, 4.8$ Hz, 1H), 3.87 (s, 3H), 3.52 (dd, $J = 7.5, 5.4$ Hz, 1H), 3.41 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 194.5, 163.7, 138.5 (2), 137.8, 131.1, 129.2, 128.5 (2), 128.3, 128.1, 128.0 (2), 127.9, 127.8, 127.7, 113.8, 102.6, 80.2, 79.2, 78.5, 74.5, 73.7, 73.4, 72.9, 56.5, 55.6; HRMS (ESI) m/z calcd for C₃₅H₃₆O₇Na [M + Na]⁺ 591.2359, found 591.2359.




13k

(2R,3R,4S,5S,6R)-2-(Acetoxymethyl)-6-(((2S,3S,4S,5R,6R)-4,5-bis(benzyloxy)-6-methoxy-2-(4-methoxybenzoyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (13k)

According to the general protocol A, (2R,3R,4S,5S,6R)-2-(acetoxymethyl)-6-(((2R,3S,4R,5R,6R)-4,5-bis(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate¹ (771 mg, 0.080 mmol), *S*-phenyl 4-methoxybenzothioate (9.80 mg, 0.040 mmol), Pd₂(dba)₃ (0.900 mg, 0.0010 mmol), ligand **L6** (3.20 mg, 0.0040 mmol), CuCl (4.00 mg, 0.040 mmol) in 1,4-dioxane (0.800 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 1:1) **13k** (27.2 mg, 84%) as a colorless oil: $[a]_D^{20} = +28.5$ ($c = 1.43$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.05 (d, $J = 8.9$ Hz, 2H), 7.30 – 7.21 (m, 8H), 7.19 – 7.16 (m, 2H), 7.01 (d, $J = 8.9$ Hz, 2H), 5.41 (d, $J = 1.8$ Hz, 1H), 5.21 (dd, $J = 3.3, 1.6$ Hz, 1H), 5.03 – 4.98 (m, 2H), 4.91 (d, $J = 11.1$ Hz, 1H), 4.85 (dd, $J = 10.1, 3.4$ Hz, 1H), 4.72 (d, $J = 9.4$ Hz, 1H), 4.68 (d, $J = 11.1$ Hz, 1H), 4.61 (d, $J = 11.1$ Hz, 1H), 4.49 (d, $J = 7.5$ Hz, 1H), 4.25 (t, $J = 9.2$ Hz, 1H), 4.00 (dd, $J = 12.4, 4.4$ Hz, 1H), 3.88 (s, 3H), 3.83 – 3.77 (m, 2H), 3.57 (dd, $J = 9.0, 7.6$ Hz, 1H), 3.50 (s, 3H), 3.21 – 3.18 (m, 1H), 2.10 (s, 3H), 1.91 – 1.89 (m, 9H); ¹³C NMR (126 MHz, CDCl₃) δ = 192.2, 171.0, 170.0, 169.7, 169.6, 164.4, 138.2, 138.1, 131.6, 128.7, 128.5, 128.3, 128.2, 127.9, 127.5, 127.4, 114.3, 105.3, 98.1, 84.7, 82.0, 75.3 (2), 74.6, 73.7,


69.2, 69.0 (2), 65.3, 61.7, 57.4, 55.7, 20.9, 20.8, 20.7, 20.6; HRMS (ESI) m/z calcd for $C_{42}H_{48}O_{16}Na$ $[M + Na]^+$ 831.2840, found 831.2850.



15

S-Phenyl (R)-2,2-dimethyl-1,3-dioxolane-4-carbothioate (15).


At room temperature, (*S*)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (396 mg, 3.00 mmol) was dissolved in CH_2Cl_2 (18.0 mL) and H_2O (6.00 mL), then treated with TEMPO (70.3 mg, 0.450 mmol) and BAIB (1.93 g, 6.00 mmol). After vigorous stirring overnight, the reaction mixture was quenched with saturated $Na_2S_2O_3$ solution, extracted with CH_2Cl_2 (3×20.0 mL), washed once with brine, dried over Na_2SO_4 , concentrated under reduced pressure, and used for next step without further purification. According to the general protocol *B*, this crude product, Ph_2S_2 (720 mg, 3.30 mmol), and $P(n-Bu)_3$ (0.816 mL, 3.30 mmol) were dissolved in anhydrous CH_2Cl_2 (30.0 mL). The reaction mixture stirred under N_2 at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO_2 (Hexanes:EtOAc, 10:1) afforded **15** (155 mg, 22%) as a white solid: $[a]_D^{20} = +105.6$ ($c = 0.85$, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$) δ 7.43 – 7.40 (m, 5H), 4.68 – 4.66 (m, 1H), 4.29 (t, $J = 8.2$ Hz, 1H), 4.18 (dd, $J = 8.9, 4.4$ Hz, 1H), 1.68 (s, 3H), 1.45 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) $\delta = 200.8, 134.8, 129.6, 129.4, 127.3, 112.3, 80.5, 68.2, 26.1, 25.2$; HRMS (ESI) m/z calcd for $C_{12}H_{14}O_3SNa$ $[M + Na]^+$ 261.0561, found 261.0569.



16

S-Phenyl (S)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)ethanethioate (16).


According to the general protocol *B*, (*S*)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)acetic acid (348 mg, 2.00 mmol), Ph_2S_2 (480 mg, 2.20 mmol), and $P(n-Bu)_3$ (0.544 mL, 2.20 mmol) were dissolved in anhydrous CH_2Cl_2 (20.0 mL). The reaction mixture stirred under N_2 at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO_2 (Hexanes:EtOAc, 8:1) afforded **16** (446 mg, 84%) as a white solid: $[a]_D^{20} = -17.5$ ($c = 0.82$, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$) δ 7.44 – 7.41 (m, 5H), 4.77 (dd, $J = 6.8, 3.5$ Hz, 1H), 3.27 (dd, $J = 16.7, 3.4$ Hz, 1H), 3.11 (dd, $J = 16.7, 6.9$ Hz, 1H), 1.61 (s, 3H), 1.55 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) $\delta = 193.3, 172.0, 134.6, 129.9, 129.4, 126.9, 111.5, 70.6, 44.6, 27.0, 25.9$; HRMS (ESI) m/z calcd for $C_{13}H_{14}O_4SNa$ $[M + Na]^+$ 289.0510, found 289.0506.



17

2-(Benzyloxy)-1-((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-yl)ethan-1-one (17).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 2-(benzyloxy)ethanethioate **14** (25.8 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **17** (52.0 mg, 89%) as a colorless oil: $[\alpha]_D^{20} = +47.6$ (*c* = 0.26, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.24 (m, 20H), 4.78 – 4.75 (m, 2H), 4.64 – 4.61 (m, 3H), 4.56 – 4.51 (m, 2H), 4.49 – 4.44 (m, 2H), 4.41 – 4.39 (m, 3H), 4.08 (dd, *J* = 8.3, 2.7 Hz, 1H), 3.78 (dd, *J* = 5.4, 2.8 Hz, 1H), 3.68 (d, *J* = 5.0 Hz, 1H), 3.47 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 203.5, 138.4, 138.1, 137.8, 137.5, 128.5 (3), 128.3, 128.0 (2), 127.9 (2), 127.8, 101.0, 75.4 (2), 74.2, 73.8, 73.7, 73.3, 73.2, 72.9, 72.5, 57.8; ¹³C NMR (126 MHz, CDCl₃) δ = 203.5, 138.4, 138.1, 137.8, 137.5, 128.5 (3), 128.3, 128.0 (2), 127.9 (2), 127.8, 101.0, 75.4 (2), 74.2, 73.8, 73.7, 73.3, 73.2, 72.9, 72.5, 57.8; HRMS (ESI) *m/z* calcd for C₃₆H₃₈O₇Na [M + Na]⁺ 605.2515, found 605.2514.



18

2-(Benzyloxy)-1-((2*S*,3*S*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-one (18).

According to the general protocol A, tributyl((2*R*,3*S*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl 2-(benzyloxy)ethanethioate **14** (25.8 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **18** (88.0 mg, 50%) as a colorless oil: $[\alpha]_D^{20} = +4.66$ (*c* = 1.60, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.23 (m, 20H), 4.99 (d, *J* = 10.9 Hz, 1H), 4.85 – 4.80 (m, 3H), 4.70 – 4.53 (m, 5H), 4.31 – 4.22 (m, 3H), 4.02 (t, *J* = 9.3 Hz, 1H), 3.72 (t, *J* = 9.4 Hz, 1H), 3.54 (dd, *J* = 9.6, 3.4 Hz, 1H), 3.36 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 203.6, 138.6, 138.0, 137.9, 137.2, 128.6 (2), 128.5 (2), 128.3, 128.2 (2), 128.1, 128.0 (2), 127.9, 127.8, 98.9, 81.8, 79.5, 78.7, 76.0, 75.3, 74.0, 73.7, 73.4, 71.0, 55.8; HRMS (ESI) *m/z* calcd for C₃₆H₃₈O₇Na [M + Na]⁺ 605.2515, found 605.2507.




19

((*R*)-2,2-Dimethyl-1,3-dioxolan-4-yl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (19).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl (*R*)-2,2-dimethyl-1,3-dioxolane-4-carbothioate **15** (23.8 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **19** (38.0 mg, 68%) as a white solid: $[\alpha]_D^{20} = +72.8$ (*c* = 0.21, CHCl₃); ¹H NMR (500 MHz,


CDCl₃) δ 7.35 – 7.25 (m, 15H), 4.83 (t, J = 6.5 Hz, 1H), 4.80 (s, 1H), 4.75 (d, J = 12.4 Hz, 1H), 4.63 (d, J = 11.9 Hz, 1H), 4.60 (d, J = 7.8 Hz, 1H, H-5), 4.58 – 4.49 (m, 4H), 4.20 (t, J = 7.9 Hz, 1H), 4.15 – 4.12 (m, 2H), 3.77 (dd, J = 5.7, 2.9 Hz, 1H), 3.69 (d, J = 5.7 Hz, 1H), 3.52 (s, 3H), 1.43 (s, 3H), 1.41 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 203.9, 138.5, 138.3, 138.1, 128.5, 128.3, 127.9 (2), 127.8 (2), 110.9, 101.3, 78.5, 75.6, 74.5, 74.1, 73.9, 73.4, 73.3, 72.8, 65.8, 57.9, 26.1, 25.6; HRMS (ESI) m/z calcd for C₃₃H₃₈O₈Na [M + Na]⁺ 585.2464, found 585.2456.



20

(*S*)-2,2-dimethyl-5-(2-oxo-2-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethyl)-1,3-dioxolan-4-one (20).

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl (*S*)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)ethanethioate **16** (26.6 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 4:1) **20** (51.5 mg, 87%) as a colorless oil: $[\alpha]_D^{20}$ = +73.9 (c = 0.21, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.35 – 7.25 (m, 15H), 4.81 (dd, J = 6.6, 3.7 Hz, 1H), 4.77 (d, J = 1.8 Hz, 1H), 4.74 (d, J = 12.4 Hz, 1H), 4.64 (d, J = 11.9 Hz, 1H), 4.57 – 4.52 (m, 3H), 4.45 (d, J = 11.6 Hz, 1H), 4.32 (d, J = 7.8 Hz, 1H, H-5), 4.06 (dd, J = 7.8, 2.7 Hz, 1H), 3.76 (dd, J = 5.6, 2.7 Hz, 1H), 3.69 (dd, J = 5.7, 1.8 Hz, 1H), 3.53 (s, 3H), 3.27 (dd, J = 18.2, 3.6 Hz, 1H), 3.14 (dd, J = 18.3, 6.7 Hz, 1H), 1.60 (s, 3H), 1.56 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 202.8, 172.9, 138.4, 138.2, 137.9, 128.5 (2), 128.4, 127.9 (2), 127.8, 111.1, 100.9, 78.0, 75.5, 74.5, 73.8, 73.5, 73.3, 72.7, 69.8, 58.0, 40.5, 26.9, 25.9; HRMS (ESI) m/z calcd for C₃₄H₃₈O₉Na [M + Na]⁺ 613.2414, found 613.2411.




21

(2*S*,3*S*,4*S*,5*R*,6*S*)-3,4,5-Tris(benzyloxy)-2-(3-(benzyloxy)prop-1-en-2-yl)-6-methoxytetrahydro-2*H*-pyran (21).

Under N₂, 2-(benzyloxy)-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-one **17** (39.6 mg, 0.068 mmol) was dissolved in THF (3.40 ml), then TMSCH₂MgCl (0.105 ml, 0.136 mmol, 1.3 M in THF) was added at 0 °C. The solution was warmed up to room temperature, stirred overnight, quenched with H₂O, and extracted with CH₂Cl₂ (3×). The combined organic layers were dried (Na₂SO₄), concentrated, and directly used next step without further purification. The crude material was dissolved with THF (3.40 mL), KHMDS was added (0.136 ml, 0.136 mmol, 1.0 M in THF) at 0 °C. The solution was warmed up to room temperature and stirred overnight, quenched with H₂O, and extracted with CH₂Cl₂ (3×). The combined organic layers were dried (Na₂SO₄), concentrated, and purified by column chromatography on SiO₂ (Hexanes:EtOAc, 8:1) to yield **21** (32.1 mg, 81%) as a pale yellow oil:


$[\alpha]_D^{20} = +43.2$ ($c = 1.63$, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.38 – 7.22 (m, 20H), 5.44 (s, 2H), 4.82 (d, $J = 12.6$ Hz, 1H), 4.76 (s, 1H), 4.61 (d, $J = 12.2$ Hz, 1H), 4.58 (d, $J = 11.9$ Hz, 1H), 4.54 (d, $J = 12.0$ Hz, 1H), 4.48 – 4.45 (m, 2H), 4.40 – 4.37 (m, 2H), 4.31 (d, $J = 11.7$ Hz, 1H), 4.22 – 4.16 (m, 2H), 3.79 (dd, $J = 9.8, 2.8$ Hz, 1H), 3.73 (t, $J = 3.4$ Hz, 1H), 3.60 (d, $J = 3.5$ Hz, 1H), 3.52 (s, 3H); $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 143.5, 138.8$ (2), 138.4, 138.3, 128.4 (4), 128.0 (2), 127.9, 127.8, 127.7 (2), 127.5, 115.0, 100.6, 76.1, 75.7, 74.2, 74.0, 73.7, 73.1, 72.4, 71.9, 70.6, 57.3; HRMS (ESI) m/z calcd for $\text{C}_{37}\text{H}_{40}\text{O}_6\text{Na}$ $[\text{M} + \text{Na}]^+$ 603.2723, found 603.2719.



22

(2*S*,3*S*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-2-(1-((*S*)-2,2-dimethyl-1,3-dioxolan-4-yl)vinyl)-6-methoxytetrahydro-2*H*-pyran (22).

Under N_2 , ((*R*)-2,2-dimethyl-1,3-dioxolan-4-yl)((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone **19** (44.6 mg, 0.079 mmol) was dissolved in THF (4.00 ml), then $\text{TMSCH}_2\text{MgCl}$ (0.122 ml, 0.159 mmol, 1.3 M in THF) was added at 0 °C. The solution was warmed up to room temperature, stirred overnight, quenched with H_2O , and extracted with CH_2Cl_2 (3 \times). The combined organic layers were dried (Na_2SO_4), concentrated, and directly to use next step without further purification. The crude material was dissolved with THF (4.00 mL), KHMDS was added (0.159 ml, 0.159 mmol, 1.0 M in THF) at 0 °C. The solution was warmed up to room temperature and stirred overnight, quenched with H_2O , and extracted with CH_2Cl_2 (3 \times). The combined organic layers were dried (Na_2SO_4), concentrated, and purified by column chromatography on SiO_2 (Hexanes:EtOAc, 5:1) to yield **22** (28.5 mg, 64%) as a white solid: $[\alpha]_D^{20} = +65.5$ ($c = 1.02$, CHCl_3); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.36 – 7.19 (m, 15H), 5.56 (s, 1H), 5.42 (s, 1H), 4.84 (d, $J = 12.6$ Hz, 1H), 4.74 – 4.71 (m, 2H), 4.57 (d, $J = 12.1$ Hz, 1H), 4.48 – 4.43 (m, 2H), 4.35 (d, $J = 11.5$ Hz, 1H), 4.30 (d, $J = 11.5$ Hz, 1H), 4.23 (d, $J = 9.3$ Hz, 1H, H-5), 4.15 (dd, $J = 7.8, 6.3$ Hz, 1H), 3.76 – 3.72 (m, 2H), 3.69 (t, $J = 8.0$ Hz, 1H), 3.61 (d, $J = 3.2$ Hz, 1H), 3.51 (s, 3H), 1.46 (s, 3H), 1.41 (s, 3H); $^{13}\text{C NMR}$ (126 MHz, CDCl_3) $\delta = 144.5, 138.8, 138.2, 138.0, 128.5$ (2), 128.4, 128.0 (2), 127.9 (2), 127.8 (2), 113.8, 109.0, 100.7, 77.2, 76.7, 75.6, 73.9, 73.1, 72.7, 71.7, 70.1, 57.4, 26.5, 26.2; HRMS (ESI) m/z calcd for $\text{C}_{34}\text{H}_{40}\text{O}_7\text{Na}$ $[\text{M} + \text{Na}]^+$ 583.2672, found 583.2670.




23

(2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-Tris(benzyloxy)-2-(3-(benzyloxy)prop-1-en-2-yl)-6-methoxytetrahydro-2*H*-pyran (23).

Under N_2 , 2-(benzyloxy)-1-((2*S*,3*S*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-one **18** (27.1 mg, 0.047 mmol) was dissolved in THF (2.30 ml), then $\text{TMSCH}_2\text{MgCl}$ (0.072 ml, 0.093 mmol, 1.3 M in THF) was added at 0 °C. The solution was warmed up to room temperature, stirred overnight, quenched with H_2O , and extracted with CH_2Cl_2 (3 \times). The combined organic layers were dried (Na_2SO_4), concentrated, and directly to use next step without further purification. The crude material was dissolved with THF (2.30 mL), KHMDS


was added (0.093 ml, 0.093 mmol, 1.0 M in THF) at 0 °C. The solution was warmed up to room temperature and stirred overnight, quenched with H₂O, and extracted with CH₂Cl₂ (3×). The combined organic layers were dried (Na₂SO₄), concentrated, and purified by column chromatography on SiO₂ (Hexanes:EtOAc, 4:1) to yield **23** (17.5 mg, 65%) as a pale yellow oil: $[\alpha]_D^{20} = -5.04$ ($c = 0.84$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.23 (m, 20H), 5.43 (s, 1H), 5.38 (s, 1H), 4.97 (d, $J = 10.8$ Hz, 1H), 4.84 – 4.80 (m, 2H), 4.76 (d, $J = 10.7$ Hz, 1H), 4.69 (d, $J = 12.2$ Hz, 1H), 4.61 – 4.57 (m, 2H), 4.54 (d, $J = 12.1$ Hz, 1H), 4.49 (d, $J = 12.0$ Hz, 1H), 4.17 (d, $J = 9.9$ Hz, 1H, H-5), 4.09 (d, $J = 13.1$ Hz, 1H), 4.04 (d, $J = 13.1$ Hz, 1H), 3.99 (t, $J = 9.2$ Hz, 1H), 3.56 – 3.49 (m, 2H), 3.36 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 143.2, 138.9, 138.4$ (2), 128.6, 128.5 (2), 128.4, 128.2, 128.1, 128.0 (2), 127.7 (3), 116.3, 98.3, 82.2, 81.5, 80.0, 76.0, 74.9, 73.5, 72.5, 71.5, 70.6, 55.3; HRMS (ESI) m/z calcd for C₃₇H₄₀O₆Na [M + Na]⁺ 603.2723, found 603.2715.



24

(2*S*,3*S*,4*S*,5*R*,6*S*)-3,4,5-Tris(benzyloxy)-2-(2-(benzyloxy)ethyl)-6-methoxytetrahydro-2*H*-pyran (24).


A solution of 2-(benzyloxy)-1-((2*S*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-ol **26** (45.2 mg, 0.077 mmol) in 1:1 THF:CS₂ (3.80 mL) was treated with a 60% dispersion of NaH in mineral oil (9.30 mg, 0.232 mmol) at 0 °C. The ice bath was removed after a brief period and the reaction mixture was stirred for 1 h at rt, then treated with CH₃I (0.048 mL, 0.773 mmol) and stirred overnight. The reaction mixture was quenched with saturated NH₄Cl solution (1.00 mL), extracted with CH₂Cl₂ (3 × 10.0 mL), washed with brine (4.00 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography on SiO₂ (Hexanes:EtOAc, 4:1) to yield the xanthate (51.5 mg, 99%) as a yellow oil. This was redissolved in degassed toluene (3.00 mL) and treated with Bu₃SnH (0.110 mL, 0.409 mmol) and AIBN (6.30 mg, 0.038 mmol), then heated to 140 °C and stirred for another 1 h. The reaction mixture was allowed to cool to rt, and the volatiles were removed under reduced pressure. The residue was purified by column chromatography on SiO₂ (Hexanes:EtOAc, 4:1) to yield **24** (29.6 mg, 68%) as a colorless oil: $[\alpha]_D^{20} = +21.3$ ($c = 1.54$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.20 (m, 20H), 4.82 (d, $J = 12.7$ Hz, 1H), 4.68 (s, 1H), 4.56 – 4.46 (m, 5H), 4.42 – 4.36 (m, 2H), 4.00 – 3.96 (m, 1H), 3.72 – 3.66 (m, 3H), 3.62 (d, $J = 3.9$ Hz, 1H), 3.56 (dd, $J = 9.4, 2.5$ Hz, 1H), 3.46 (s, 3H), 2.32 – 2.25 (m, 1H), 1.86 – 1.79 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 138.8, 138.7, 138.3, 138.1, 128.4$ (3), 128.1, 128.0 (2), 127.8 (2), 127.5, 100.3, 77.0, 75.5, 73.9, 73.6, 73.0, 72.9, 71.9, 70.1, 66.9, 57.0, 32.3; HRMS (ESI) m/z calcd for C₃₆H₄₀O₆Na [M + Na]⁺ 591.2723, found 591.2713.



25

1-((*R*)-2,2-Dimethyl-1,3-dioxolan-4-yl)-1-((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-ol (25).


Under N_2 , ((*R*)-2,2-dimethyl-1,3-dioxolan-4-yl)((*2R,3R,4S,5R,6S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone **19** (28.9 mg, 0.051 mmol) was dissolved in anhydrous THF (2.60 mL), then MeMgBr was added (0.051 ml, 0.154 mmol, 3.0 M in diethyl ether) at 0 °C. The solution was warmed up to room temperature, stirred overnight, quenched with H_2O , and extracted with CH_2Cl_2 (3 \times). The combined organic layers were dried (Na_2SO_4), concentrated, and purified by column chromatography on SiO_2 (Hexanes:EtOAc, 2:1) to yield **25** (29.1 mg, 98%, d.r. = 2.3:1) as a colorless oil. Characterization data for the major configurational product: $[\alpha]_D^{20} = +32.6$ (c = 1.31, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$) δ 7.37 – 7.28 (m, 13H), 7.23 – 7.21 (m, 2H), 4.83 – 4.78 (m, 2H), 4.55 (d, $J = 12.0$ Hz, 1H), 4.50 (d, $J = 12.4$ Hz, 1H), 4.47 (d, $J = 12.0$ Hz, 1H), 4.41 (d, $J = 11.4$ Hz, 1H), 4.38 – 4.35 (m, 2H), 4.05 (dd, $J = 8.5, 6.6$ Hz, 1H), 3.98 – 3.94 (m, 2H), 3.87 (d, $J = 8.6$ Hz, 1H, H-5), 3.82 (dd, $J = 4.9, 2.9$ Hz, 1H), 3.68 (dd, $J = 4.9, 1.5$ Hz, 1H), 3.54 (s, 3H), 3.19 (s, 1H), 1.43 (s, 3H), 1.31 (s, 3H), 1.25 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) $\delta = 138.7, 138.2, 137.7, 128.6, 128.5$ (2), 128.0 (2), 127.9, 109.0, 100.9, 78.4, 76.1, 75.7, 74.4, 74.2, 74.0, 73.2, 71.2, 65.1, 57.6, 26.5, 25.1, 19.4; HRMS (ESI) m/z calcd for $C_{34}H_{42}O_8Na$ $[M + Na]^+$ 601.2777, found 601.2772.



26

2-(Benzyloxy)-1-((*2S,3R,4S,5R,6S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-ol (26).

Under N_2 , 2-(benzyloxy)-1-((*2R,3R,4S,5R,6S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)ethan-1-one **17** (41.2 mg, 0.071 mmol) was dissolved in EtOH (3.50 ml), then $NaBH_4$ (53.5 mg, 1.41 mmol) was added at 0 °C. The solution was allowed to warm to room temperature and stirred overnight. After removal of the solvent under reduced pressure, the residue was dissolved in ethyl acetate (16.0 mL) and successively washed with saturated aqueous NH_4Cl (4.00 mL) and 1 N HCl (4.00 mL). The aqueous layers were back-extracted with ethyl acetate (3 \times). The combined organic layers were dried (Na_2SO_4), concentrated and directly purified by column chromatography on SiO_2 (Hexanes:EtOAc, 2:1) to yield **26** (40.1 mg, 97%, d.r. = 4.7:1) as a colorless oil. Characterization data for the major configurational product: $[\alpha]_D^{20} = +22.4$ (c = 0.84, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$) δ 7.36 – 7.20 (m, 20H), 4.81 (d, $J = 12.6$ Hz, 1H), 4.71 (d, $J = 1.6$ Hz, 1H), 4.55 – 4.46 (m, 5H), 4.39 (d, $J = 11.5$ Hz, 1H), 4.32 (d, $J = 11.5$ Hz, 1H), 4.11 – 4.08 (m, 1H), 3.98 (dd, $J = 8.7, 5.7$ Hz, 1H, H-5), 3.91 (dd, $J = 8.7, 2.6$ Hz, 1H), 3.78 (dd, $J = 4.4, 2.8$ Hz, 1H), 3.67 – 3.64 (m, 3H), 3.45 (s, 3H), 3.25 (s, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) $\delta = 138.6, 138.5, 138.2, 137.5, 128.6, 128.5$ (2), 128.4, 128.2, 128.1 (2), 127.9, 127.6, 100.7, 75.8, 75.4, 74.1, 73.5, 73.3, 72.9, 72.7, 72.5, 71.3, 70.9, 57.3; HRMS (ESI) m/z calcd for $C_{36}H_{40}O_7Na$ $[M + Na]^+$ 607.2672, found 607.2667.




28

Se-Phenyl-S-butyl selenothiolate (28).


Under N_2 , Ph_2Se_2 (312 mg, 1.00 mmol) and $NaBH_4$ (75.7 mg, 2.00 mmol) were dissolved in anh. EtOAc (10.0 mL) and stirred at 40 °C for 1 h. The mixture was cooled to rt before the dropwise

addition of *S*-butyl chlorothioformate (0.325 mL, 2.10 mmol). After 2 h, TLC indicated completion; the mixture was concentrated and purified by chromatography on SiO₂ (Hexanes) to afford **28** (458 mg, 84%) as a pale yellow oil: ¹H NMR (500 MHz, CDCl₃) δ 7.63 (d, *J* = 6.9 Hz, 2H), 7.45 – 7.38 (m, 3H), 2.95 (t, *J* = 7.4 Hz, 2H), 1.62 – 1.56 (m, 2H), 1.40 – 1.33 (m, 2H), 0.90 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 186.6, 136.7, 129.6 (2), 126.1, 31.7, 31.4, 21.9, 13.6; HRMS (ESI) *m/z* calcd for C₁₁H₁₅OSSe [M + H]⁺ 275.0009, found 275.0017.




***S*-Butyl (2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbothioate (29).**

According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *Se*-phenyl-*S*-butyl selenothiolate **28** (27.3 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) **29** (52.9 mg, 96%) as a white solid: [*a*]_D²⁰ = +52.8 (c = 0.53, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.23 (m, 15H), 4.80 – 4.77 (m, 2H), 4.64 (d, *J* = 12.0 Hz, 1H), 4.58 – 4.52 (m, 3H), 4.46 – 4.42 (m, 2H), 4.14 (dd, *J* = 7.9, 2.8 Hz, 1H), 3.79 (dd, *J* = 5.4, 2.8 Hz, 1H), 3.69 (dd, *J* = 5.6, 1.8 Hz, 1H), 3.53 (s, 3H), 2.93 (t, *J* = 7.3 Hz, 2H), 1.62 – 1.56 (m, 2H), 1.46 – 1.38 (m, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 197.6, 138.6, 138.3, 138.0, 128.4, 128.2, 127.9 (2), 127.8 (3), 101.1, 78.7, 75.4, 75.0, 74.8, 73.8, 73.3, 72.8, 57.8, 31.5, 28.3, 22.1, 13.7; HRMS (ESI) *m/z* calcd for C₃₂H₃₈O₆SNa [M + Na]⁺ 573.2287, found 573.2281.



((2*S*,3*S*,4*S*,5*R*,6*S*)-3,4,5-Tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanol (30).


Under N₂, *S*-butyl (2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbothioate **29** (30.8 mg, 0.056 mmol) was dissolved in EtOH (2.80 ml), then NaBH₄ (42.3 mg, 1.12 mmol) was added at 0 °C. The solution was allowed to warm to room temperature and stirred overnight. After removal of the solvent under reduced pressure, the residue was dissolved in ethyl acetate (16.0 mL) and successively washed with saturated aqueous NH₄Cl (4.00 mL) and 1 N HCl (4.00 mL). The aqueous layers were back-extracted with ethyl acetate (3×). The combined organic layers were dried (Na₂SO₄), concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 2:1) to yield **30** (20.7 mg, 80%) as a colorless oil: [*a*]_D²⁰ = +25.8 (c = 1.09, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.20 (m, 15H), 4.79 – 4.77 (m, 2H), 4.56 (d, *J* = 12.1 Hz, 1H), 4.49 – 4.46 (m, 2H), 4.42 (s, 2H), 3.94 – 3.89 (m, 2H), 3.83 – 3.73 (m, 3H), 3.61 (d, *J* = 4.0 Hz, 1H), 3.53 (s, 3H), 2.17 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ = 138.5, 138.2, 138.0, 128.5 (2), 128.2, 128.0 (2), 127.9 (2), 100.5, 75.5, 73.9, 73.7, 73.5, 73.1, 73.0, 71.9, 63.0, 57.4; HRMS (ESI) *m/z* calcd for C₂₈H₃₂O₆Na [M + Na]⁺ 487.2097, found 487.2093.



31b

***S*-Butyl (2*R*,3*R*,5*R*,6*S*)-3,5-bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbothioate (31b).**


According to the general protocol A, ((2*S*,3*R*,5*R*,6*S*)-3,5-bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)tributylstannane **9h** (123 mg, 0.200 mmol), *Se*-phenyl-*S*-butyl selenothiolate **28** (27.3 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) **31b** (39.7 mg, 89%) as a colorless oil: $[\alpha]_D^{20} = +32.8$ (c = 0.26, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.27 (m, 10H), 4.70 (d, *J* = 12.5 Hz, 1H), 4.61 – 4.58 (m, 2H), 4.50 (d, *J* = 11.6 Hz, 1H), 4.47 (d, *J* = 11.6 Hz, 1H), 4.16 – 4.10 (m, 2H), 3.80 – 3.77 (m, 1H), 3.53 (s, 3H), 2.97 – 2.87 (m, 2H), 2.24 – 2.19 (m, 1H), 1.81 – 1.76 (m, 1H), 1.62 – 1.56 (m, 2H), 1.45 – 1.38 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 197.9, 138.7, 138.0, 128.5, 128.4, 127.9, 127.8, 127.7, 102.0, 81.3, 72.4, 72.1 (2), 71.8, 57.9, 31.5, 30.2, 28.3, 22.1, 13.7; HRMS (ESI) *m/z* calcd for C₂₅H₃₂O₅SNa [M + Na]⁺ 467.1868, found 467.1860.



32

((2*S*,3*R*,5*R*,6*S*)-3,5-Bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanol (32).

Under N₂, *S*-butyl (2*R*,3*R*,5*R*,6*S*)-3,5-bis(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbothioate **31b** (30.6 mg, 0.069 mmol) was dissolved in EtOH (3.40 ml), then NaBH₄ (52.1 mg, 1.38 mmol) was added at 0 °C. The solution was allowed to warm to room temperature and stirred overnight. After removal of the solvent under reduced pressure, the residue was dissolved in ethyl acetate (16.0 mL) and successively washed with saturated aqueous NH₄Cl (4.00 mL) and 1 N HCl (4.00 mL). The aqueous layers were back-extracted with ethyl acetate (3×). The combined organic layers were dried (Na₂SO₄), concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:1) to yield **32** (22.4 mg, 91%) as a colorless oil: $[\alpha]_D^{20} = +21.9$ (c = 0.58, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.27 (m, 10H), 4.76 (d, *J* = 12.6 Hz, 1H), 4.59 (d, *J* = 12.6 Hz, 1H), 4.52 – 4.44 (m, 3H), 3.90 (dd, *J* = 11.7, 3.1 Hz, 1H), 3.81 – 3.72 (m, 3H), 3.54 – 3.51 (m, 4H), 2.35 – 2.29 (m, 2H), 1.57 – 1.52 (m, 1H); ¹³C NMR (126 MHz, CDCl₃) δ = 138.8, 138.1, 128.6, 128.4, 128.0 (2), 127.9, 127.7, 102.7, 78.4, 73.6, 72.6, 71.5, 71.0, 63.3, 57.2, 32.3; HRMS (ESI) *m/z* calcd for C₂₁H₂₆O₅Na [M + Na]⁺ 381.1678, found 381.1675.




33

(2*R*,3*S*,4*R*,5*S*,6*S*)-4,5-Bis(benzyloxy)-2-(hydroxymethyl)-6-methoxytetrahydro-2*H*-pyran-3-ol (33).


Under N₂, a mixture of (4*aR*,6*S*,7*S*,8*S*,8*aR*)-6-methoxy-2-phenylhexahydropyrano[3,2-*d*][1,3]dioxine-7,8-diol⁸ (9.25 g, 32.8 mmol) and TBAI (2.42 g, 6.55 mmol) was dissolved in DMF

(200 mL). To the stirred solution, NaH (60% in oil, 3.93 g, 98.3 mmol) was added in an ice bath, followed shortly by the addition of benzyl bromide (9.70 mL, 81.7 mmol). The ice bath was then removed, and the reaction mixture was stirred at rt overnight. The reaction mixture was diluted with ethyl acetate, washed with water (3 × 50 mL) and brine, dried over anhydrous Na₂SO₄, concentrated under reduced pressure, and used directly in the next step without further purification. The crude material and *p*-TsOH (2.86 g, 16.6 mmol) were added to MeOH (120 mL) and DCM (180 mL). After stirring at rt overnight, the reaction mixture was quenched with Et₃N (0.910 mL) and concentrated under reduced pressure. The crude product was purified by chromatographic purification on SiO₂ (CH₂Cl₂: EtOAc, 1:1) to afford **33** (8.34 g, 68%) as a white solid: $[\alpha]_D^{20} = +36.0$ (c = 1.31, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.26 (m, 10H), 4.84 (s, 1H), 4.63 (d, *J* = 12.3 Hz, 1H), 4.57 – 4.52 (m, 3H), 4.20 – 3.72 (m, 5H), 3.58 (s, 1H), 3.45 (s, 3H), 3.32 (s, 1H), 2.45 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ = 137.8, 136.9, 128.7, 128.6, 128.3, 128.1, 128.0, 127.8, 99.9, 73.7, 72.7, 71.9, 68.3, 67.2, 63.7, 55.6; HRMS (ESI) *m/z* calcd for C₂₁H₂₆O₆Na [M + Na]⁺ 397.1627, found 397.1620.



***S*-Butyl (2*R*,3*R*,4*R*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbothioate (**34**).**


According to the general protocol A, tributyl((2*S*,3*R*,4*S*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane **9k** (145 mg, 0.200 mmol), *Se*-phenyl-*S*-butyl selenothiolate **28** (27.3 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) **34** (50.4 mg, 91%) as a pale yellow oil: $[\alpha]_D^{20} = +11.6$ (c = 0.29, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.35 – 7.24 (m, 15H), 4.90 – 4.86 (m, 2H), 4.78 (d, *J* = 11.0 Hz, 1H), 4.73 – 4.69 (m, 2H), 4.60 (d, *J* = 10.4 Hz, 1H), 4.38 (d, *J* = 7.7 Hz, 1H), 3.95 (d, *J* = 9.5 Hz, 1H, H-5), 3.79 (t, *J* = 9.2 Hz, 1H), 3.66 (t, *J* = 8.9 Hz, 1H), 3.58 (s, 3H), 3.50 – 3.46 (m, 1H), 2.93 (t, *J* = 7.3 Hz, 2H), 1.61 – 1.55 (m, 2H), 1.44 – 1.36 (m, 2H), 0.90 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 196.5, 138.5, 138.4, 137.9, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8 (2), 104.9, 84.0, 81.7, 79.8, 79.7, 75.9, 75.3, 74.9, 57.4, 31.3, 28.4, 22.1, 13.7; HRMS (ESI) *m/z* calcd for C₃₂H₃₈O₆SNa [M + Na]⁺ 573.2287, found 573.2281.



((2*S*,3*S*,4*R*,5*S*,6*S*)-3,4,5-Tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanol (35**).**

Under N₂, *S*-butyl (2*R*,3*R*,4*R*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-carbothioate **34** (38.4 mg, 0.070 mmol) was dissolved in EtOH (3.50 mL), then NaBH₄ (52.8 mg, 1.39 mmol) was added at 0 °C. The solution was allowed to warm to room temperature and stirred overnight. After removal of the solvent under reduced pressure, the residue was dissolved in ethyl acetate (16.0 mL) and successively washed with saturated aqueous NH₄Cl (4.00 mL) and 1 N HCl


(4.00 mL). The aqueous layers were back-extracted with ethyl acetate (3×). The combined organic layers were dried (Na₂SO₄), concentrated and directly purified by column chromatography on SiO₂ (Hexanes:EtOAc, 2:1) to yield **35** (23.5 mg, 73%) as a white solid: $[\alpha]_D^{20} = -6.15$ (c = 0.84, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.27 (m, 15H), 4.96 – 4.91 (m, 2H), 4.88 (d, *J* = 10.9 Hz, 1H), 4.83 (d, *J* = 10.9 Hz, 1H), 4.73 (d, *J* = 11.0 Hz, 1H), 4.66 (d, *J* = 10.9 Hz, 1H), 4.37 (d, *J* = 7.8 Hz, 1H), 3.89 (dd, *J* = 11.9, 2.6 Hz, 1H), 3.74 (dd, *J* = 11.9, 4.5 Hz, 1H), 3.69 (t, *J* = 9.1 Hz, 1H), 3.61 – 3.57 (m, 4H), 3.43 – 3.37 (m, 2H), 1.86 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ = 138.6, 138.5, 138.1, 128.6, 128.5 (2), 128.2, 128.1, 128.0, 127.8 (2), 104.9, 84.6, 82.5, 77.7, 75.8, 75.2, 75.1, 75.0, 62.1, 57.4; HRMS (ESI) *m/z* calcd for C₂₈H₃₂O₆Na [M + Na]⁺ 487.2097, found 487.2093.



36

S-Phenyl ferrocenecarbothioate (**36**).


According to the general protocol B, ferrocenecarboxylic acid (460 mg, 2.00 mmol), Ph₂S₂ (480 mg, 2.20 mmol), and P(*n*-Bu)₃ (0.544 mL, 2.20 mmol) were dissolved in anh. CH₂Cl₂ (20.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 20:1) afforded **36** (593 mg, 92%) as a orange-red solid: ¹H NMR (500 MHz, CDCl₃) δ 7.52 – 7.41 (m, 5H), 4.93 (s, 2H), 4.53 (s, 2H), 4.29 (s, 5H); ¹³C NMR (126 MHz, CDCl₃) δ = 191.8, 135.1, 129.3, 129.2, 128.0, 78.9, 72.1, 70.8, 69.3; HRMS (ESI) *m/z* calcd for C₁₇H₁₄OSFeNa [M + Na]⁺ 345.0012, found 345.0011.



39

Ferrocenyl ((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (**39**).


According to the general protocol A, tributyl((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane¹ (145 mg, 0.200 mmol), *S*-phenyl ferrocenecarbothioate **36** (32.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) **39** (55.0 mg, 85%) as a orange-red oil: $[\alpha]_D^{20} = +74.0$ (c = 1.87, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.27 (m, 15H), 4.92 – 4.91 (m, 2H), 4.77 – 4.69 (m, 7H), 4.63 (d, *J* = 12.0 Hz, 1H), 4.52 (d, *J* = 20.3 Hz, 2H), 4.41 – 4.39 (m, 1H), 4.13 (s, 5H), 4.03 (dd, *J* = 7.3, 3.1 Hz, 1H), 3.86 (dd, *J* = 7.1, 2.5 Hz, 1H), 3.24 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 200.4, 138.8 (2), 138.4, 128.5 (2), 128.4 (2), 127.9 (2), 127.7 (2), 101.5, 77.3, 76.1, 76.0, 75.5, 73.7 (2), 73.5, 73.3, 72.7, 72.4, 70.4, 70.0, 69.7, 57.9; HRMS (ESI) *m/z* calcd for C₃₈H₃₈O₆FeNa [M + Na]⁺ 669.1916, found 669.1908.



40

Ferrocenyl ((2*S*,3*S*,4*S*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanone (40).


According to the general protocol A, tributyl((2*R*,3*S*,4*R*,5*S*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)stannane **9f** (145 mg, 0.200 mmol), *S*-phenyl ferrocenecarbothioate **36** (32.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 6:1) **40** (33.9 mg, 52%) as a orange-red solid: $[\alpha]_D^{20} = -20.7$ ($c = 0.81$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.29 (m, 10H), 7.24 – 7.15 (m, 5H), 4.96 (s, 1H), 4.91 (s, 1H), 4.84 – 4.74 (m, 4H), 4.69 (d, $J = 11.8$ Hz, 1H), 4.65 (d, $J = 11.8$ Hz, 1H), 4.59 (d, $J = 10.5$ Hz, 1H), 4.55 – 4.49 (m, 3H), 4.39 (t, $J = 9.4$ Hz, 1H), 4.22 (s, 5H), 3.99 (dd, $J = 9.4, 3.0$ Hz, 1H), 3.84 – 3.83 (m, 1H), 3.50 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 199.7, 138.6, 138.4, 128.5, 128.4, 128.2, 128.0, 127.8, 127.7$ (2), 127.6, 100.5, 79.7, 77.8, 75.9, 75.2, 74.6, 73.5, 73.0, 72.9, 72.7, 72.4, 70.5, 69.9 (2), 55.9; HRMS (ESI) m/z calcd for C₃₈H₃₈O₆FeNa [M + Na]⁺ 669.1916, found 669.1913.



41

((2*S*,3*S*,4*S*,5*R*,6*R*)-5-(Benzyloxy)-6-methoxy-3,4-bis(naphthalen-2-ylmethoxy)tetrahydro-2*H*-pyran-2-yl)(ferrocenyl)methanone (41).

According to the general protocol A, ((2*R*,3*S*,4*R*,5*R*,6*R*)-5-(benzyloxy)-6-methoxy-3,4-bis(naphthalen-2-ylmethoxy)tetrahydro-2*H*-pyran-2-yl)tributylstannane¹ (165 mg, 0.200 mmol), *S*-phenyl ferrocenecarbothioate **36** (32.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 8:1) **41** (39.6 mg, 53%) as a orange-red solid: $[\alpha]_D^{20} = -54.6$ ($c = 1.20$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.84 – 7.83 (m, 1H), 7.79 – 7.72 (m, 4H), 7.67 (d, $J = 8.4$ Hz, 1H), 7.63 – 7.62 (m, 1H), 7.54 (s, 1H), 7.50 – 7.39 (m, 7H), 7.35 – 7.29 (m, 3H), 7.26 – 7.25 (m, 1H), 5.15 (d, $J = 11.3$ Hz, 1H), 5.04 (d, $J = 11.3$ Hz, 1H), 4.99 (d, $J = 11.1$ Hz, 1H), 4.96 – 4.93 (m, 2H), 4.87 – 4.84 (m, 2H), 4.79 (d, $J = 11.1$ Hz, 1H), 4.61 (s, 1H), 4.57 (s, 1H), 4.55 (d, $J = 7.6$ Hz, 1H), 4.35 (d, $J = 9.6$ Hz, 1H, H-5), 4.25 (d, $J = 1.2$ Hz, 5H), 4.13 (t, $J = 9.3$ Hz, 1H), 3.89 (t, $J = 9.1$ Hz, 1H), 3.64 – 3.58 (m, 4H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 198.4, 138.6, 136.2, 135.6, 133.4, 133.3, 133.1, 133.0, 128.5, 128.2, 128.1, 128.0$ (2), 127.8 (2), 127.7, 127.1, 126.5 (2), 126.1, 126.0, 125.9 (3), 105.6, 84.5, 82.1, 78.9, 77.7, 76.0, 75.8, 75.3, 74.9, 73.3, 73.1, 70.3, 70.0, 69.7, 57.4; HRMS (ESI) m/z calcd for C₄₆H₄₂O₆FeNa [M + Na]⁺ 769.2229, found 769.2234.




42

((2*S*,3*S*,4*R*,5*R*,6*R*)-3,4-Bis(benzyloxy)-5-(dibenzylamino)-6-methoxytetrahydro-2*H*-pyran-2-yl)(ferrocenyl)methanone (42).

According to the general protocol A, (2*R*,3*R*,4*R*,5*S*,6*R*)-*N,N*-dibenzyl-4,5-bis(benzyloxy)-2-methoxy-6-(tributylstannyl)tetrahydro-2*H*-pyran-3-amine **9j** (163 mg, 0.200 mmol), *S*-phenyl ferrocenecarbothioate **36** (32.2 mg, 0.100 mmol), Pd₂(dba)₃ (2.30 mg, 0.0025 mmol), ligand **L6** (8.00 mg, 0.010 mmol), CuCl (9.90 mg, 0.100 mmol) in 1,4-dioxane (2.00 mL) heated under Ar at 90 °C for 72 h afforded after chromatographic purification on SiO₂ (Hexanes:EtOAc, 8:1) **42** (47.7 mg, 65%) as a orange-red oil: $[\alpha]_D^{20} = -27.5$ ($c = 2.56$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.44 – 7.34 (m, 9H), 7.30 – 7.21 (m, 9H), 7.14 – 7.12 (m, 2H), 5.05 (d, $J = 11.2$ Hz, 1H), 4.96 – 4.87 (m, 3H), 4.71 (d, $J = 10.3$ Hz, 1H), 4.66 – 4.64 (m, 2H), 4.59 – 4.58 (m, 2H), 4.31 (d, $J = 9.4$ Hz, 1H, H-5), 4.24 (s, 5H), 4.12 – 4.05 (m, 3H), 3.97 (t, $J = 9.2$ Hz, 1H), 3.88 (d, $J = 13.8$ Hz, 2H), 3.53 (s, 3H), 3.08 (dd, $J = 9.4, 7.1$ Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) $\delta = 198.8, 139.7, 139.1, 138.1, 129.1, 128.5, 128.4, 128.3, 127.7, 127.4$ (2), 127.0, 103.9, 80.9, 79.3, 77.7, 76.2, 75.0, 74.3, 73.2, 72.9, 70.1, 70.0, 69.9, 63.7, 56.5, 55.1; HRMS (ESI) m/z calcd for C₄₅H₄₆NO₅Fe [M + H]⁺ 736.2725, found 736.2718.


6. Detailed Experimental Procedures for Compounds S1-S11



S1

S-Phenyl 4-benzoylbenzothioate (S1).


According to the general protocol B, 4-benzoylbenzoic acid (452 mg, 2.00 mmol), Ph₂S₂ (480 mg, 2.20 mmol), and P(*n*-Bu)₃ (0.544 mL, 2.20 mmol) were dissolved in anh. CH₂Cl₂ (20.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) afforded **S1** (578 mg, 91%) as a white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.13 (d, *J* = 8.4 Hz, 2H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.83 – 7.81 (m, 2H), 7.65 – 7.62 (m, 1H), 7.56 – 7.47 (m, 7H); ¹³C NMR (126 MHz, CDCl₃) δ = 195.9, 189.9, 142.0, 139.4, 137.0, 135.1, 133.2, 130.3 (2), 129.9, 129.5, 128.7, 127.5, 127.0; HRMS (ESI) *m/z* calcd for C₂₀H₁₅O₂S [M + H]⁺ 319.0793, found 319.0791.



S2

S-Phenyl 4-phenoxybenzothioate (S2).


According to the general protocol B, 4-phenoxybenzoic acid (428 mg, 2.00 mmol), Ph₂S₂ (480 mg, 2.20 mmol), and P(*n*-Bu)₃ (0.544 mL, 2.20 mmol) were dissolved in anh. CH₂Cl₂ (20.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 20:1) afforded **S2** (607 mg, 99%) as a white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, *J* = 8.6 Hz, 2H), 7.53 – 7.40 (m, 7H), 7.22 (t, *J* = 7.4 Hz, 1H), 7.09 (d, *J* = 8.0 Hz, 2H), 7.03 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (126 MHz, CDCl₃) δ = 188.8, 162.7, 155.4, 135.3, 131.1, 130.2, 129.8, 129.6, 129.4, 127.5, 124.9, 120.4, 117.5; HRMS (ESI) *m/z* calcd for C₁₉H₁₄O₂SNa [M + Na]⁺ 329.0612, found 329.0611.



S3

S-Phenyl 1-methyl-1H-indole-5-carbithioate (S3).


According to the general protocol B, 1-methyl-1H-indole-5-carboxylic acid (210 mg, 1.20 mmol), Ph₂S₂ (288 mg, 1.32 mmol), and P(*n*-Bu)₃ (0.326 mL, 1.32 mmol) were dissolved in anh. CH₂Cl₂ (18.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) afforded **S3** (303 mg, 95%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.43 (d, *J* = 1.6 Hz, 1H), 7.92 (dd, *J* = 8.7, 1.7 Hz, 1H), 7.58 – 7.55 (m, 2H), 7.49 – 7.44 (m, 3H), 7.36 (d, *J* = 8.7 Hz, 1H), 7.14 (d, *J* = 3.2 Hz, 1H), 6.64 (dd, *J* = 3.1, 0.9 Hz, 1H), 3.83 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 190.1, 139.6, 135.4, 130.8, 129.3, 129.2, 128.6, 128.4, 128.1, 122.3, 121.2, 109.3, 103.2, 33.2; HRMS (ESI) *m/z* calcd for C₁₆H₁₃NOSNa [M + Na]⁺ 290.0616, found 290.0617.



S4

S-Phenyl benzo[*d*]oxazole-6-carbothioate (S4).


According to the general protocol B, benzo[*d*]oxazole-6-carboxylic acid (326 mg, 2.00 mmol), Ph₂S₂ (480 mg, 2.20 mmol), and P(*n*-Bu)₃ (0.544 mL, 2.20 mmol) were dissolved in anh. CH₂Cl₂ (20.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) afforded **S4** (375 mg, 73%) as a pale yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 13.2 Hz, 2H), 8.12 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.89 (d, *J* = 8.4 Hz, 1H), 7.56 – 7.47 (m, 5H); ¹³C NMR (126 MHz, CDCl₃) δ = 189.5, 155.4, 150.0, 144.4, 135.2, 134.5, 129.9, 129.5, 127.1, 124.5, 120.9, 110.8; HRMS (ESI) *m/z* calcd for C₁₄H₁₀NO₂S [M + H]⁺ 256.0432, found 256.0430.



S5

S-Phenyl 4-([1,1'-biphenyl]-4-yl)-4-oxobutanethioate (S5).


According to the general protocol B, Fenbufen (509 mg, 2.00 mmol), Ph₂S₂ (480 mg, 2.20 mmol), and P(*n*-Bu)₃ (0.544 mL, 2.20 mmol) were dissolved in anh. CH₂Cl₂ (20.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) afforded **S5** (684 mg, 99%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, *J* = 8.3 Hz, 2H), 7.69 (d, *J* = 8.3 Hz, 2H), 7.63 (d, *J* = 7.5 Hz, 2H), 7.49 – 7.39 (m, 8H), 3.41 (t, *J* = 6.6 Hz, 2H), 3.17 (t, *J* = 6.6 Hz, 2H); ¹³C NMR (126 MHz, CDCl₃) δ = 197.2, 197.0, 146.1, 139.9, 135.2, 134.7, 129.6, 129.3, 129.1, 128.8, 128.4, 127.7, 127.4 (2), 37.6, 33.7; HRMS (ESI) *m/z* calcd for C₂₂H₁₈O₂SNa [M + Na]⁺ 369.0925, found 369.0921.



S6

S-Phenyl (*S*)-2-(4-isobutylphenyl)propanethioate (S6).


According to the general protocol B, (*S*)-(+)-Ibuprofen (413 mg, 2.00 mmol), Ph₂S₂ (480 mg, 2.20 mmol), and P(*n*-Bu)₃ (0.544 mL, 2.20 mmol) were dissolved in anh. CH₂Cl₂ (20.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) afforded **S6** (590 mg, 99%) as a white solid: [*a*]_D²⁰ = +194.4 (c = 0.61, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.36 (m, 5H), 7.27 (d, *J* = 8.0 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 4.01 – 3.97 (m, 1H), 2.49 (d, *J* = 7.2 Hz, 2H), 1.92 – 1.84 (m, 1H), 1.58 (d, *J* = 7.1 Hz, 3H), 0.93 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (126 MHz, CDCl₃) δ = 199.4, 141.2, 136.8, 134.6, 129.6, 129.3, 129.2, 128.2, 127.9, 53.9, 45.2, 30.3, 22.5, 18.8; HRMS (ESI) *m/z* calcd for C₁₉H₂₂OSNa [M + Na]⁺ 321.1289, found 321.1296.



S7

S-Phenyl (S)-2-(3-benzoylphenyl)propanethioate (S7).


According to the general protocol B, (S)-(+)-Ketoprofen (509 mg, 2.00 mmol), Ph₂S₂ (480 mg, 2.20 mmol), and P(*n*-Bu)₃ (0.544 mL, 2.20 mmol) were dissolved in anh. CH₂Cl₂ (20.0 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 10:1) afforded **S7** (675 mg, 97%) as a white solid: $[\alpha]_D^{20} = +170.6$ (c = 0.76, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.84 – 7.82 (m, 3H), 7.74 (d, *J* = 7.6 Hz, 1H), 7.62 – 7.59 (m, 2H), 7.51 – 7.47 (m, 3H), 7.40 – 7.35 (m, 5H), 4.11 – 4.07 (m, 1H), 1.62 (d, *J* = 7.1 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 198.7, 196.5, 140.0, 138.2, 137.6, 134.5, 132.7, 132.0, 130.2, 129.8, 129.5 (2), 129.3, 128.9, 128.4, 127.7, 53.9, 18.8; HRMS (ESI) *m/z* calcd for C₂₂H₁₈O₂SNa [M + Na]⁺ 369.0925, found 369.0922.



S8

(2S,3R,4R,5S,6S)-4,5-Bis(benzyloxy)-6-methoxy-2-(tributylstannyl)tetrahydro-2H-pyran-3-ol (S8).


According to the general protocol C, to a solution of (2*S*,3*S*,4*R*)-3,4-bis(benzyloxy)-2-methoxy-3,4-dihydro-2*H*-pyran **S9** (3.43 g, 10.5 mmol) in a cooled (0 °C), vigorously stirring biphasic solution of CH₂Cl₂ (87.0 mL), saturated aq. NaHCO₃ (146 mL), and acetone (18.0 mL), a solution of Oxone® (25.8 g, 42.0 mmol) in H₂O (102 mL) was added dropwise over 15 min. The reaction mixture was stirred at 0 °C for 0.5 h then at rt for 2 h, the organic phase was separated, and extracted with CH₂Cl₂ (2 × 30.0 mL). The combined organic layers were dried (Na₂SO₄) and concentrated to afford the epoxide as a white solid. The crude epoxide was dissolved in anh. and degassed THF (26.0 mL), cooled to -15 °C, and a solution of MeMgSnBu₃ (5.19 g, 15.8 mmol) in THF was added. The reaction was stirred at -15 °C for 1.5 h, then warmed to -10 °C and stirred for 1 h, quenched with H₂O (30.0 mL), filtered twice through Celite®, and the organic phase was separated. The aqueous phase was extracted with CH₂Cl₂ (3 × 30.0 mL), and the combined organic layers were dried (Na₂SO₄), concentrated, and purified by column chromatography on SiO₂ (Hexanes:EtOAc, 1:0 then 15:1) to afford **S8** (1.15 g, 17%) as a colorless oil: $[\alpha]_D^{20} = -6.92$ (c = 0.77, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.28 (m, 10H), 4.99 – 4.94 (m, 2H), 4.70 (d, *J* = 11.1 Hz, 1H), 4.66 (d, *J* = 11.2 Hz, 1H), 4.15 (d, *J* = 7.4 Hz, 1H), 3.72 – 3.68 (m, 1H), 3.55 (s, 3H), 3.42 – 3.31 (m, 3H), 2.15 (s, 1H), 1.57 – 1.47 (m, 6H), 1.35 – 1.28 (m, 6H), 0.97 – 0.88 (m, 15H); ¹³C NMR (126 MHz, CDCl₃) δ = 138.7, 128.7, 128.5, 128.3, 128.2, 128.0, 127.8, 108.1, 86.4, 82.6, 75.5, 74.7, 73.4, 69.9, 57.0, 29.2, 27.6, 13.9, 9.0; HRMS (ESI) *m/z* calcd for C₃₂H₅₀O₅SnNa [M + Na]⁺ 657.2578, found 657.2582.



S9

(2S,3S,4R)-3,4-Bis(benzyloxy)-2-methoxy-3,4-dihydro-2H-pyran (S9).


At room temperature, (2*R*,3*S*,4*R*,5*S*,6*S*)-4,5-bis(benzyloxy)-2-(hydroxymethyl)-6-methoxytetrahydro-2*H*-pyran-3-ol **33** (5.29 g, 14.1 mmol) was dissolved in CH₂Cl₂ (85.0 mL) and H₂O (28.0 mL), then treated with TEMPO (0.331 g, 2.12 mmol) and BAIB (9.10 g, 28.3 mmol). After vigorous stirring overnight, the reaction mixture was quenched with saturated Na₂S₂O₃ solution, extracted with CH₂Cl₂ (3 × 30.0 mL), washed once with brine, dried over Na₂SO₄, concentrated under reduced pressure, and used for next step without further purification. A solution of the crude carboxylic acid (~5.49 g, 14.1 mmol) in degassed DMF (141 mL) was treated with DMF dineopentyl acetal (16.3 g, 19.7 mL, 70.6 mmol) in a high-pressure reaction vessel. The reaction mixture was heated at 200 °C for 6 h and then cooled to room temperature. It was diluted with ethyl acetate and washed with water (3 × 50 mL), followed by a single wash with brine. The organic layer was dried over anhydrous Na₂SO₄ and purified by silica gel chromatography (hexanes/EtOAc = 10:1) to afford **S9** (2.97 g, 22%) as a yellow solid: $[\alpha]_D^{20} = -5.98$ (c = 1.23, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.28 (m, 10H), 6.35 (dd, *J* = 6.2, 1.4 Hz, 1H), 4.94 (dd, *J* = 6.2, 3.2 Hz, 1H), 4.83 – 4.79 (m, 2H), 4.70 (d, *J* = 11.7 Hz, 1H), 4.63 (d, *J* = 12.1 Hz, 1H), 4.60 (d, *J* = 12.1 Hz, 1H), 4.09 – 4.07 (m, 1H), 3.75 – 3.73 (m, 1H), 3.57 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 142.1, 138.5, 138.2, 128.5 (2), 128.1, 127.9, 127.7, 101.7, 101.6, 77.4, 73.6, 73.3, 71.0, 57.1; HRMS (ESI) *m/z* calcd for C₂₀H₂₂O₄Na [M + Na]⁺ 349.1416, found 349.1419.



S10

((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-Tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methyl 4-((phenylthio)carbonyl)benzoate (S10**)**

According to the general protocol B, 4-(((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methoxy)carbonyl)benzoic acid **S11** (221 mg, 0.361 mmol), Ph₂S₂ (86.6 mg, 0.397 mmol), and P(*n*-Bu)₃ (98.1 μL, 0.398 mmol) were dissolved in anh. CH₂Cl₂ (3.60 mL). The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 5:1) afforded **S10** (249 mg, 98%) as a white solid: $[\alpha]_D^{20} = +45.7$ (c = 0.83, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.10 – 8.05 (m, 4H), 7.54 – 7.47 (m, 5H), 7.39 – 7.27 (m, 14H), 7.24 – 7.21 (m, 1H), 5.03 (d, *J* = 10.7 Hz, 1H), 4.93 (d, *J* = 11.0 Hz, 1H), 4.86 (d, *J* = 10.7 Hz, 1H), 4.82 (d, *J* = 12.1 Hz, 1H), 4.69 (d, *J* = 12.1 Hz, 1H), 4.64 – 4.62 (m, 2H), 4.56 (dd, *J* = 11.9, 1.9 Hz, 1H), 4.48 (dd, *J* = 11.9, 4.8 Hz, 1H), 4.07 (t, *J* = 9.2 Hz, 1H), 3.98 – 3.95 (m, 1H), 3.60 – 3.56 (m, 2H), 3.40 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 189.8, 165.3, 140.2, 138.6, 138.2, 137.9, 135.1, 134.3, 130.1, 129.9, 129.5, 128.7, 128.6, 128.2 (3), 128.1 (2), 127.9, 127.5, 126.9, 98.2, 82.2, 80.2, 77.5, 76.1, 75.2, 73.6, 68.7, 64.1, 55.4; HRMS (ESI) *m/z* calcd for C₄₂H₄₀O₈SNa [M + Na]⁺ 727.2342, found 727.2350.



S11

4-(((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-Tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methoxy)carbonyl)benzoic acid (S11**)**

Under N₂, ((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2*H*-pyran-2-yl)methanol (465 mg, 1.00 mmol) was dissolved in DCM (5.00 ml). Terephthalic acid (249 mg, 1.50 mmol), EDCI (345 mg, 1.80 mmol), DMAP (36.7 mg, 0.300 mmol), and DIPEA (233 mg, 1.80 mmol) were then added. The reaction mixture stirred under N₂ at rt overnight, the volatiles were removed *in vacuo*, and chromatographic purification on SiO₂ (Hexanes:EtOAc, 1:1) afforded **S11** (405 mg, 66%) as a white solid: $[\alpha]_D^{20} = +53.1$ (c = 0.71, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.10 (d, *J* = 8.3 Hz, 2H), 8.02 (d, *J* = 8.3 Hz, 2H), 7.34 – 7.25 (m, 9H), 7.23 – 7.21 (m, 5H), 7.19 – 7.15 (m, 1H), 4.99 (d, *J* = 10.7 Hz, 1H), 4.88 (d, *J* = 11.0 Hz, 1H), 4.81 (d, *J* = 10.7 Hz, 1H), 4.77 (d, *J* = 12.1 Hz, 1H), 4.64 (d, *J* = 12.1 Hz, 1H), 4.59 – 4.57 (m, 2H), 4.51 (dd, *J* = 11.9, 2.2 Hz, 1H), 4.43 (dd, *J* = 11.9, 4.6 Hz, 1H), 4.03 (t, *J* = 9.2 Hz, 1H), 3.93 – 3.90 (m, 1H), 3.58 – 3.54 (m, 2H), 3.35 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ = 170.5, 165.4, 138.5, 138.1, 137.8, 134.5, 133.3, 130.3, 129.8, 128.7, 128.6 (2), 128.3, 128.2 (3), 128.1, 128.0, 98.2, 82.3, 80.1, 77.4, 76.2, 75.2, 73.6, 68.8, 64.1, 55.4; HRMS (ESI) *m/z* calcd for C₃₆H₃₆O₉Na [M + Na]⁺ 635.2257, found 635.2257.


7. References

- 1 G. Cheng, B. Yang, Y. Han, W. Lin, S. Tao, Y. Nian, Y. Li, M. A. Walczak and F. Zhu, Pd-Catalyzed Stereospecific Glycosyl Cross-Coupling of Reversed Anomeric Stannanes for Modular Synthesis of Nonclassical C-Glycosides, *Precis. Chem.*, 2024, **2**, 587-599.
- 2 F. P. Boulineau and A. Wei, Synthesis of L-sugars from 4-deoxypentenositides, *Org. Lett.*, 2002, **4**, 2281-2283.
- 3 H. Aoyama, Y. Iizuka, R. Kawanishi, K. Shibatomi, Y. Arakawa, H. Tsuji, Y. Hirose and M. Mishima, Efficient synthesis of γ -oxo carboxylic esters and isotope-labeled 5-aminolevulinic acid (5-ALA) by Pd(OAc)₂/phosphonium tetrafluoroborates catalyzed Fukuyama coupling reaction, *Tetrahedron Lett.*, 2023, **123**, 154570.
- 4 Z. Zhou, J. Yang, B. Yang, Y. Han, L. Zhu, X.-S. Xue and F. Zhu, Photoredox Nickel-Catalysed Stille Cross-Coupling Reactions, *Angew. Chem. Int. Ed.*, 2023, **62**, e202314832.
- 5 G. Sun, J. Li, X. Liu, Y. Liu, X. Wen, H. Sun and Q.-L. Xu, Organophosphorus-Catalyzed “Dual-Substrate Deoxygenation” Strategy for C–S Bond Formation from Sulfonyl Chlorides and Alcohols/Acids, *J. Org. Chem.*, 2023, **88**, 8628-8635.
- 6 J. Su, A. Chen, G. Zhang, Z. Jiang and J. Zhao, Photocatalytic Phosphine-Mediated Thioesterification of Carboxylic Acids with Disulfides, *Org. Lett.*, 2023, **25**, 8033-8037.
- 7 K. Wu, T.-Z. Wang and Y.-F. Liang, Nickel-Catalyzed Reductive Coupling of Carboxylic Acids with Disulfides to Access Thioesters, *Adv. Synth. Catal.*, 2023, **365**, 4233-4240.
- 8 H.-M. Liu, Y. Sato and Y. Tsuda, Chemistry of Oxo-Sugars. (2). Regio- and Stereo-Selective Synthesis of Methyl D-Hexopyranosiduloses and Identification of Their Forms Existing in Solutions, *Chem. Pharm. Bull.*, 1993, **41**, 491-501.


8. Copies of 1D and 2D NMR Spectra

8.04
8.02
7.56
7.55
7.53
7.48
7.46
7.45
7.42
7.40
7.39
7.38
7.36
7.33
7.32
7.31
7.30
7.29
7.29
7.28
7.27
5.02
5.01
4.79
4.77
4.76
4.75
4.73
4.72
4.71
4.67
4.65
4.54
4.54
4.53
4.14
4.13
4.12
4.12
3.98
3.97
3.96
3.96
2.90


12a (^1H NMR, 500MHz, CDCl_3)




12a




12a (^{13}C NMR, 126MHz, CDCl_3)




12a







12a (¹H-¹³C Coupled HSQC)




12a







12a (¹H-¹H NOESY)




12a




12b (^1H NMR, 500MHz, CDCl_3)



12b





12b (^{13}C NMR, 126MHz, CDCl_3)




12b

195.44
163.39
138.79
138.77
138.36
131.67
128.60
128.42
128.40
128.11
127.95
127.84
127.74
127.70
127.64
113.64
101.70
77.16
75.90
75.59
75.54
74.35
73.71
73.34
73.24
57.81
55.50







12b (^1H - ^{13}C Coupled HSQC)




12b




$J = 143 \text{ Hz}$



12b (^1H - ^1H NOESY)




12b




8.14
8.12
7.72
7.70
7.40
7.39
7.38
7.36
7.33
7.32
7.29
4.98
4.97
4.77
4.76
4.74
4.72
4.62
4.60
4.50
4.49
4.48
4.09
4.08
4.07
4.07
3.96
3.95
3.94
3.94
-2.94

12c (^1H NMR, 500MHz, CDCl_3)



12c




196.00
138.62
138.59
138.16
138.05
134.64
134.38
134.12
133.86
129.72
128.51
128.49
128.17
128.01
127.91
127.86
127.80
126.95
125.56
125.53
125.51
125.48
124.78
122.61
120.44


101.85

77.16
75.92
75.77
75.12
74.05
73.92
73.45
73.21
57.99


12c (^{13}C NMR, 126MHz, CDCl_3)



12c





12c (^{19}F NMR, 471MHz, CDCl_3)




12c

63.05







12c (¹H-¹³C Coupled HSQC)




12c






12d (^1H NMR, 500MHz, CDCl_3)




12d

8.12
8.10
7.70
7.69
7.66
7.64
7.50
7.49
7.47
7.43
7.41
7.40
7.39
7.37
7.36
7.34
7.33
7.31
7.30
7.29
5.04
5.03
4.77
4.76
4.74
4.72
4.67
4.64
4.55
4.54
4.53
4.15
4.13
3.98
3.96
2.98





12d (¹³C NMR, 126MHz, CDCl₃)




12d

196.57
145.63
139.91
138.79
138.78
138.34
134.33
130.00
129.07
128.48
128.47
128.46
128.37
128.16
128.00
127.90
127.81
127.77
127.71
127.34
127.08
101.83
77.16
75.95
75.77
75.50
74.37
73.82
73.42
73.29
57.93







12d (^1H - ^{13}C Coupled HSQC)




12d

$J = 145 \text{ Hz}$







12d (^1H - ^1H NOESY)




12d




12e (¹H NMR, 500MHz, CDCl₃)



12e





12e (^{13}C NMR, 126MHz, CDCl_3)




12e

196.98
138.81
138.76
138.34
135.58
132.82
132.48
131.41
129.84
128.62
128.47
128.44
128.33
128.13
127.98
127.89
127.84
127.77
127.74
127.70
126.75
124.80
101.85
77.16
75.99
75.84
75.56
74.45
73.81
73.42
73.30
57.90







12e (^1H - ^{13}C Coupled HSQC)




12e






12e (¹H-¹H NOESY)




12e




8.14
8.12
7.87
7.85
7.81
7.79
7.65
7.63
7.62
7.53
7.51
7.50
7.41
7.39
7.37
7.36
7.34
7.33
7.32
7.31
7.29
7.29
7.28
5.03
5.02
4.77
4.76
4.75
4.74
4.73
4.72
4.65
4.63
4.53
4.52
4.51
4.11
4.10
4.09
4.08
3.97
3.96
3.95
3.94
2.98

12f (¹H NMR, 500MHz, CDCl₃)



12f






196.44
196.04

141.10
138.61
138.14
138.12
136.97
133.05
130.14
129.92
129.22
128.56
128.47
128.45
128.13
127.97
127.87
127.85
127.80
127.74
101.82


77.16
75.81
75.78
75.22
74.14
73.86
73.41
73.22
57.99

12f (¹³C NMR, 126MHz, CDCl₃)







12f (¹H-¹³C Coupled HSQC)




12f







12f (¹H-¹H NOESY)




12f




12g (¹H NMR, 500MHz, CDCl₃)



12g




12g (^{13}C NMR, 126MHz, CDCl_3)




12g

195.33
166.62
164.59
138.67
138.19
132.10
132.02
131.92
131.89
128.46
128.14
127.97
127.87
127.83
127.79
127.72
115.70
115.53

101.77
77.16
75.82
75.73
75.29
74.17
73.82
73.39
73.22
57.88





12g (^{19}F NMR, 471MHz, CDCl_3)




12g


104.82









12g (^1H - ^1H NOESY)




12g




12h (^{13}C NMR, 126MHz, CDCl_3)




12h







12h (¹H-¹³C Coupled HSQC)




12h






12h (¹H-¹H NOESY)




12h




8.06
8.04
7.43
7.42
7.41
7.40
7.40
7.39
7.37
7.36
7.34
7.33
7.33
7.32
7.31
7.30
7.29
7.28
7.24
7.22
7.21
7.10
7.08
7.02
7.00
4.99
4.98
4.79
4.77
4.75
4.72
4.66
4.63
4.52
4.52
4.51
4.51
4.14
4.13
4.12
4.12
3.97
3.96
3.95
3.94
3.03

12i (^1H NMR, 500MHz, CDCl_3)



12i




—195.37


161.91
155.48
138.74
138.31
131.70
130.21
130.14
128.44
128.42
128.41
128.12
127.94
127.84
127.76
127.72
127.67
124.72
120.28
117.16
—101.72


77.16
75.88
75.67
75.43
74.31
73.75
73.36
73.20
—57.83

12i (^{13}C NMR, 126MHz, CDCl_3)




12i







12i (^1H - ^{13}C Coupled HSQC)




12i







12i (¹H-¹H NOESY)




12i




12j (¹H NMR, 500MHz, CDCl₃)



12j





12j (^{13}C NMR, 126MHz, CDCl_3)




12j

196.55
166.32
138.80
138.65
138.64
138.19
133.74
129.67
129.27
128.46
128.45
128.12
127.97
127.88
127.84
127.79
127.73
101.85
77.16
75.80
75.78
75.28
74.17
73.85
73.40
73.27
57.93
52.53







12j (^1H - ^{13}C Coupled HSQC)




12j






12j (^1H - ^1H NOESY)



12j




—195.56

138.51
138.47
137.93
132.30
129.74
128.48
128.47
128.13
127.96
127.91
127.88
127.86
127.80
118.04
116.18


—101.81


77.16
75.86
75.66
74.94
73.93
73.91
73.42
73.11
—57.97

12k (^{13}C NMR, 126MHz, CDCl_3)




12k







12k (¹H-¹³C Coupled HSQC)




12k

$J = 143$ Hz







12k (^1H - ^1H NOESY)




12k




121 (¹H NMR, 500MHz, CDCl₃)




121




12I (^{13}C NMR, 126MHz, CDCl_3)




12I







121 (¹H-¹³C Coupled HSQC)




121

$J = 142 \text{ Hz}$







12I (¹H-¹H NOESY)




12I




12m (¹H NMR, 500MHz, CDCl₃)




12m




12m (^{13}C NMR, 126MHz, CDCl_3)




12m







12m (^1H - ^{13}C Coupled HSQC)




12m

$J = 142 \text{ Hz}$







12m (^1H - ^1H NOESY)




12m




12n (^1H NMR, 500MHz, CDCl_3)




12n







12n (^1H - ^{13}C Coupled HSQC)




12n

$J = 147 \text{ Hz}$







12o (¹H NMR, 500MHz, CDCl₃)



12o



12o (¹³C NMR, 126MHz, CDCl₃)



12o

185.10

151.13

146.82

138.66

138.49

137.99

128.45

128.42

128.37

128.12

127.92

127.90

127.77

127.76

127.74

119.91

112.16

101.44

77.16

75.76

75.67

74.87

74.06

73.76


73.38

72.78


57.58

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10

f1 (ppm)





12o (¹H-¹³C Coupled HSQC)





12o


$J = 146$ Hz












12p (¹H-¹³C Coupled HSQC)




12p

$J = 140 \text{ Hz}$


f1 (ppm)

9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0


f2 (ppm)




12q (¹H NMR, 500MHz, CDCl₃)




12q




12q (^{13}C NMR, 126MHz, CDCl_3)




12q







12q (¹H-¹³C Coupled HSQC)




12q




$J = 146 \text{ Hz}$




12q (¹H-¹H NOESY)




12q







12r (^{13}C NMR, 126MHz, CDCl_3)




12r







12r (¹H-¹³C Coupled HSQC)



12r


J = 148 Hz






7.35
7.35
7.34
7.33
7.33
7.32
7.32
7.31
7.30
7.30
7.30
7.29
7.29
7.29
7.28
7.28
7.27
7.26
7.26
7.25
7.25
7.24
7.21
7.20
7.19
7.19
7.18
7.18
4.79
4.77
4.76
4.76
4.64
4.62
4.59
4.57
4.55
4.53
4.40
4.39
4.24
4.22
4.07
4.06
4.05
3.79
3.79
3.72
3.71
3.71
3.70
3.50
2.94
2.93
2.93
2.92
2.92
2.91
2.90


12s (¹H NMR, 500MHz, CDCl₃)



12s





12s (^{13}C NMR, 126MHz, CDCl_3)




12s

141.19
138.57
138.28
137.93
128.52
128.49
128.47
128.27
127.97
127.91
127.83
126.13
101.07
77.69
77.16
75.51
74.31
73.87
73.71
73.23
72.31
-57.91
-40.87
-29.41







12s (¹H-¹³C Coupled HSQC)




12s

$J = 149$ Hz







12s (¹H-¹H NOESY)




12s




12t (¹H NMR, 500MHz, CDCl₃)




12t




12t (^{13}C NMR, 126MHz, CDCl_3)




12t







12t (^1H - ^{13}C Coupled HSQC)




12t

$J = 150$ Hz






12t (^1H - ^1H NOESY)




12t




7.43
7.42
7.39
7.36
7.36
7.34
7.32
7.31
7.29
7.28
7.26
7.25
7.22
7.21
7.19
7.11
7.11
7.10
4.78
4.76
4.70
4.68
4.60
4.58
4.56
4.54
4.46
4.44
4.43
4.41
4.38
4.35
4.33
3.67
3.46
3.46
3.46


12u (¹H NMR, 500MHz, CDCl₃)




12u




12u (^{13}C NMR, 126MHz, CDCl_3)




12u







12u (¹H-¹³C Coupled HSQC)




12u


$J = 147 \text{ Hz}$








12v (^{1}H NMR, 500MHz, CDCl_3)



12v

—199.58
—167.82

12v (¹³C NMR, 126MHz, CDCl₃)




12v


138.33
138.15
137.92
134.15
132.29
128.52
128.49
128.46
127.93
127.92
127.84
123.55

—100.79


77.32
77.16
75.40
74.69
73.84
73.71
73.36
73.08
—58.14

—44.71







12v (^1H - ^{13}C Coupled HSQC)




12v







12w (¹H NMR, 500MHz, CDCl₃)




12w




12w (^{13}C NMR, 126MHz, CDCl_3)




12w






12w (¹H-¹³C Coupled HSQC)




12w

J = 146 Hz




f1 (ppm)


f2 (ppm)




12w (^1H - ^1H NOESY)



12w




12x (¹H NMR, 500MHz, CDCl₃)




12x


8.13
8.11
7.88
7.87
7.39
7.37
7.36
7.35
7.33
7.31
7.30
7.29
4.97
4.96
4.75
4.73
4.73
4.70
4.61
4.59
4.48
4.47
4.46
4.45
4.05
4.04
3.93
3.92
3.12
3.10
3.09
2.93
1.57
1.55
1.54
1.52
1.51
1.50
0.88
0.86
0.85




12x (^{13}C NMR, 126MHz, CDCl_3)




12x





12x (¹H-¹³C Coupled HSQC)



12x


$J = 145$ Hz

f1 (ppm)


9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0

f2 (ppm)


146




12y (¹H NMR, 500MHz, CDCl₃)




12y




12y (^{13}C NMR, 126MHz, CDCl_3)




12y






12y (¹H-¹³C Coupled HSQC)




12y




J = 145 Hz

f1 (ppm)


f2 (ppm)



12y (¹H-¹H NOESY)




12y




f1 (ppm)


f2 (ppm)




12z (^{13}C NMR, 126MHz, CDCl_3)




12z







12z (^1H - ^{13}C Coupled HSQC)




12z

$J = 139 \text{ Hz}$






12z (¹H-¹H NOESY)






12z




f1 (ppm)


f2 (ppm)









12aa (^1H - ^{13}C Coupled HSQC)




12aa




$J = 142$ Hz




12aa (^1H - ^1H NOESY)




12aa







12ab (¹³C NMR, 126MHz, CDCl₃)




12ab








12ab (^1H - ^{13}C Coupled HSQC)



12ab


$J = 148 \text{ Hz}$






7.32 7.32 7.32 7.31 7.31 7.30 7.30 7.29 7.28 7.28 7.28 7.27 7.26 7.26 7.25 7.24 7.24 7.23 7.23 7.19 7.19 7.18 7.17 7.11 7.10 7.07 7.05 4.71 4.71 4.69 4.69 4.63 4.60 4.57 4.56 4.55 4.53 4.51 4.34 4.33 4.18 4.17 3.86 3.85 3.85 3.79 3.79 3.78 3.77 3.52 2.45 2.44 1.84 1.38 1.36 0.90 0.90 0.89 0.89

12ac (^1H NMR, 500MHz, CDCl_3)



12ac



—207.63


140.67
138.70
138.60
138.29
137.65
129.75
128.47
128.41
128.36
128.06
127.99
127.87
127.81
127.79
127.68
127.67
—101.78

77.16
75.91
75.17
75.16
73.87
73.42
73.15
72.90
—58.42


~47.68
~45.15


~30.29
~22.51
~22.49
~17.19

12ac (¹³C NMR, 126MHz, CDCl₃)




12ac








12ac (¹H-¹³C Coupled HSQC)





12ac

J = 151 Hz












12ad (¹H-¹³C Coupled HSQC)





12ad





7.62
7.60
7.39
7.38
7.36
7.35
7.34
7.32
7.31
7.30
7.28
7.27
7.26
7.22
7.21
7.21
7.19
7.06
7.05
7.05
6.88
6.86
6.83
5.26
5.25
4.76
4.73
4.71
4.68
4.66
4.63
4.63
4.52
4.51
4.51
4.05
3.99
3.98
3.94
3.94
3.93
3.52
2.84
2.63
1.74
1.73
1.73
1.65
1.63
1.55
1.54
1.53
1.52
1.50
1.40
1.38
1.37
0.93
0.92

12ae (^1H NMR, 500MHz, CDCl_3)



—199.23

—168.81

—158.22

—152.58

—141.43

—138.89

—138.80

—138.72

—138.59

—132.22

—128.36

—127.99

—127.97

—127.78

—127.66

—127.62

—127.54

—126.17

—125.10

—122.83

—121.38

—113.00

—101.72

77.99

77.16

75.87

75.41

74.60

73.77

73.09

72.98

64.40

57.68

49.69

46.74

44.35

26.84

25.40


24.21

22.84


22.59


14.68

12ae (^{13}C NMR, 126MHz, CDCl_3)




12ae







12ae (^1H - ^{13}C Coupled HSQC)



12ae



$J = 144$ Hz





8.04
7.38
7.37
7.36
7.35
7.34
7.33
7.33
7.32
7.30
7.30
7.29
7.28
7.28
7.27
7.26
7.25
7.22
7.21
7.21
5.04
5.02
4.97
4.96
4.93
4.91
4.86
4.84
4.83
4.80
4.75
4.74
4.73
4.71
4.71
4.69
4.68
4.67
4.63
4.63
4.62
4.61
4.53
4.53
4.50
4.49
4.48
4.07
4.05
4.05
3.94
3.94
3.61
3.59
3.59
3.57
3.57
3.39
2.89

12af (¹H NMR, 500MHz, CDCl₃)







196.41

165.41

138.90
138.62
138.60
138.52
138.16
138.08
137.81
133.45
129.70
129.24
128.59
128.57
128.55
128.45
128.43
128.21
128.15
128.11
128.08
128.00
127.95
127.87
127.85
127.83
127.78
127.71
127.71
101.84
98.11
82.16
80.09
77.46
77.16
76.04
75.78
75.26
75.15
74.14
73.84
73.50
73.39
73.28
68.69
63.97
57.96
55.24



12af (^{13}C NMR, 126MHz, CDCl_3)






7.37
7.37
7.36
7.34
7.34
7.33
7.31
7.30
7.29
7.28
7.27
4.97
4.95
4.85
4.83
4.80
4.74
4.71
4.69
4.59
4.57
4.49
4.48
4.41
4.40
3.82
3.81
3.79
3.72
3.71
3.71
3.69
3.47
3.45
3.44
1.49
1.49
1.48
1.47
1.46
1.46
1.45
1.45
1.44
1.44
1.43
1.31
1.29
1.28
1.26
1.25
1.23
0.92
0.90
0.90
0.88
0.87
0.85
0.84


9e' (¹H NMR, 500MHz, CDCl₃)





9e' (¹³C NMR, 126MHz, CDCl₃)





138.86
138.73
138.59
128.48
128.41
128.30
128.13
127.99
127.90
127.71
127.61
127.60
105.45
83.32
82.49
82.22
77.16
75.09
74.10
73.23
70.82
-55.92
29.23
27.62
13.81
10.37









9f (¹H NMR, 500MHz, CDCl₃)





9f (^{13}C NMR, 126MHz, CDCl_3)




139.1
138.8
138.6
128.5
128.4
128.3
127.9
127.8
127.7
127.6
127.6
127.4
100.0
82.5
77.6
77.2
75.2
74.4
72.7
71.8
65.1
-54.7
-29.3
-27.6
-13.8
-9.2










9h (¹³C NMR, 126MHz, CDCl₃)



9h


139.26
138.60
128.42
128.39
127.89
127.82
127.64
127.61
— 103.96
77.16
74.81
73.75
72.55
72.29
70.46
— 57.31
33.15
29.26
27.62
— 13.83
— 9.38






7.32
7.31
7.30
7.29
7.28
7.27
5.14
5.12
4.66
4.64
4.62
4.59
4.54
4.52
4.17
4.16
3.67
3.65
3.63
3.62
3.61
3.60
3.46
3.45
3.43
3.41
2.38
2.37
2.36
2.35
1.55
1.54
1.53
1.52
1.51
1.49
1.47
1.46
1.44
1.43
1.30
1.29
1.27
1.26
1.24
1.23
0.96
0.95
0.94
0.94
0.93
0.92
0.91
0.89
0.88
0.87
0.87
0.85
0.84


9i (¹H NMR, 500MHz, CDCl₃)



9i



9i (¹³C NMR, 126MHz, CDCl₃)



9i

138.94
138.37
128.59
128.33
128.04
127.83
127.79
127.53


—103.89


81.85
81.00
77.16
74.47
71.03
69.36

—56.56


36.64
29.22
27.59

—13.80
—9.21









9i (¹H-¹³C Coupled HSQC)



9i






f1 (ppm)

f2 (ppm)


195

7.44
7.43
7.41
7.38
7.37
7.36
7.35
7.35
7.34
7.32
7.29
7.29
7.28
7.27
7.27
7.26
7.26
7.25
7.23
7.23
7.22
7.21
5.15
5.13
4.97
4.95
4.83
4.80
4.60
4.59
4.56
4.36
4.35
4.10
4.07
3.95
3.92
3.59
3.47
3.45
1.51
1.50
1.49
1.48
1.47
1.31
1.30
1.28
1.27
0.96
0.94
0.94
0.92
0.92
0.91
0.90
0.90
0.88
0.87

9j (¹H NMR, 500MHz, CDCl₃)



9j




140.10
139.16
138.65
129.03
128.55
128.35
128.32
128.24
127.93
127.78
127.49
127.41
127.32
126.78
106.68

83.79
82.61
77.16
74.37
74.22
72.26
68.99
63.66
56.25
55.17


29.23
27.58


13.79
9.18


9j (¹³C NMR, 126MHz, CDCl₃)



9j









7.36
7.35
7.33
7.31
7.29
7.27
7.26
7.24
5.06
5.04
4.97
4.95
4.93
4.75
4.73
4.72
4.69
4.61
4.58
4.14
4.13
3.73
3.72
3.70
3.61
3.59
3.58
3.55
3.48
3.46
3.43
3.41
3.40
1.53
1.51
1.50
1.48
1.47
1.45
1.44
1.43
1.31
1.29
1.28
1.27
1.25
1.23
0.98
0.97
0.96
0.95
0.94
0.94
0.92
0.91
0.89
0.88
0.86
0.85


91 (^1H NMR, 500MHz, CDCl_3)



91




91 (^{13}C NMR, 126MHz, CDCl_3)





91


138.86
138.69
138.62
128.52
128.49
128.37
128.21
128.06
127.71
127.63
127.59
107.86
87.07
83.06
81.09
77.16
75.60
74.90
74.43
69.15
-56.96
29.21
27.58
-13.79
-9.19






91 (¹H-¹³C Coupled HSQC)






13a (^1H NMR, 500MHz, CDCl_3)



13a





—196.05
—163.58


138.51
138.31
131.84
128.61
128.49
128.38
128.03
128.00
127.86
—113.70

—101.62


77.16
76.09
75.41
73.71
73.46
67.22
57.95
55.54

13a (¹³C NMR, 126MHz, CDCl₃)







13a (^1H - ^{13}C Coupled HSQC)




13a




J = 140 Hz




13a (¹H-¹H NOESY)



13a




13b (^1H NMR, 500MHz, CDCl_3)




13b

7.99
7.97
7.36
7.36
7.35
7.34
7.33
7.33
7.32
7.32
7.29
7.28
7.28
7.27
6.96
6.94
4.94
4.92
4.69
4.67
4.51
4.50
4.36
4.35
4.02
4.00
3.98
3.95
3.93
3.91
3.88
3.48
3.34
3.32
3.30
2.82
1.19
1.18
1.18
1.16
1.15
1.09
1.08
1.08
1.07



13b (^{13}C NMR, 126MHz, CDCl_3)



13b

—194.66

—164.21

139.11
131.87
128.41
128.22
127.66
127.39


—113.87

—105.83

82.61
77.16
76.87
75.43
74.51
72.13


57.32
55.63

18.41
18.39
13.09







13b (¹H-¹³C Coupled HSQC)




13b

J = 140 Hz







13b (¹H-¹H NOESY)





13b




—194.60
 164.22
 138.83
 138.17
 137.86
 131.64
 129.48
 128.66
 128.54
 128.35
 128.25
 128.17
 128.05
 127.77
 127.71
 —113.98


—99.50
 81.90
 79.96
 79.59
 77.16
 76.04
 75.33
 73.83
 69.44
 56.38
 55.66

13c (¹³C NMR, 126MHz, CDCl₃)







13c (^1H - ^{13}C Coupled HSQC)




13c







13c (^1H - ^1H NOESY)



13c




13d (^1H NMR, 500MHz, CDCl_3)




13d

8.07
8.05
7.40
7.38
7.36
7.35
7.34
7.32
7.32
7.31
7.30
7.22
7.21
7.21
7.07
7.07
7.06
7.05
6.98
6.96
4.99
4.97
4.95
4.88
4.86
4.78
4.77
4.75
4.68
4.66
4.64
4.62
4.54
4.52
4.12
4.10
4.08
3.89
3.85
3.83
3.82
3.59
3.58
3.56
3.55



13d (^{13}C NMR, 126MHz, CDCl_3)



13d

—192.64

—164.05

138.64

138.52

138.01

131.64

128.98

128.48

128.29

128.19

127.93

127.79

127.72

—113.94

—105.38

84.48

82.04

79.04

77.16

75.86

75.12

74.88


74.66

~57.28


~55.60

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10


f1 (ppm)





13d (^1H - ^{13}C Coupled HSQC)




13d




13e (^{13}C NMR, 126MHz, CDCl_3)







13e (¹H-¹³C Coupled HSQC)




13e






13e (^1H - ^1H NOESY)




13e




8.09
8.07
7.86
7.85
7.84
7.81
7.79
7.78
7.77
7.77
7.76
7.75
7.65
7.64
7.62
7.60
7.60
7.51
7.50
7.49
7.48
7.45
7.44
7.43
7.43
7.42
7.42
7.40
7.36
7.34
7.34
7.33
7.17
7.16
6.94
6.92
5.19
5.16
5.07
5.05
5.03
5.00
4.95
4.93
4.84
4.81
4.79
4.77
4.75
4.73
4.58
4.57
4.19
3.94
3.84
3.68
3.67
3.66
3.58


13f (¹H NMR, 500MHz, CDCl₃)




13f




13f (^{13}C NMR, 126MHz, CDCl_3)




13f






13f (¹H-¹³C Coupled HSQC)





13f







13f (^1H - ^1H NOESY)




13g (^1H NMR, 500MHz, CDCl_3)




13g




13g (^{13}C NMR, 126MHz, CDCl_3)




—195.95 —163.32
138.63 138.27 131.74 128.73 128.50 128.46 127.90 127.85 127.79 127.75 113.63
—101.11 77.16 75.97 72.83 71.69 71.51 71.29 57.66 55.50 —26.95







13g (¹H-¹³C Coupled HSQC)




13g




J = 142 Hz



13g (¹H-¹H NOESY)



13g





f1 (ppm)


f2 (ppm)

8.05
8.04
7.39
7.38
7.37
7.37
7.36
7.36
7.35
7.35
7.33
7.32
7.32
7.31
7.30
7.23
7.23
7.22
7.22
7.21
7.21
7.20
7.12
7.11
7.10
7.10
6.95
6.94
4.84
4.82
4.75
4.72
4.69
4.67
4.66
4.64
4.59
4.58
4.57
4.56
4.55
4.54
4.03
4.01
3.99
3.88
3.85
3.84
3.82
3.82
3.81
3.46
2.39
2.39
2.38
1.77
1.76
1.74
1.74

13h (¹H NMR, 500MHz, CDCl₃)



13h (^{13}C NMR, 126MHz, CDCl_3)



—192.78

—163.92


138.35
138.28
131.66
129.08
128.56
128.27
128.22
127.83
127.80
127.66
—113.85

—101.83

79.08
79.01
77.16
75.11
75.04
71.78



56.80
55.59

—36.45







13h (¹H-¹³C Coupled HSQC)




13i (¹H NMR, 500MHz, CDCl₃)



13i



13i (^{13}C NMR, 126MHz, CDCl_3)




13i

193.31
163.91
139.66
139.03
138.10
131.64
129.02
128.98
128.37
128.28
128.27
128.15
127.65
127.44
126.98
113.88


103.75

80.81
79.43
77.16
75.26
74.78
74.40
63.80
56.41
55.57
55.07

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
f1 (ppm)





13i (¹H-¹³C Coupled HSQC)




13i

J = 143 Hz






13i (^1H - ^1H NOESY)






13i



7.93
7.91
7.35
7.35
7.34
7.33
7.32
7.31
7.30
7.30
7.29
7.29
7.28
7.27
7.27
7.18
7.17
7.17
7.17
7.16
7.15
7.15
7.13
7.13
6.99
6.98
6.97
6.90
6.88
5.25
5.24
4.88
4.87
4.84
4.82
4.78
4.76
4.69
4.68
4.66
4.65
4.59
4.57
4.34
4.32
4.11
4.09
4.09
4.08
3.99
3.98
3.98
3.97
3.87
3.53
3.52
3.51
3.50
3.41

13j (¹H NMR, 500MHz, CDCl₃)






194.49
163.69
138.47
138.47
137.80
131.11
129.19
128.55
128.47
128.26
128.11
127.99
127.97
127.86
127.75
127.66
113.82


102.64

80.25
79.21
78.51
77.16
74.51
73.71
73.41
72.94
56.45
55.61







13j (¹H-¹³C Coupled HSQC)




13j






13j (¹H-¹H NOESY)



13j





f1 (ppm)


f2 (ppm)

8.06
8.04
7.30
7.30
7.30
7.29
7.29
7.28
7.27
7.27
7.26
7.26
7.25
7.25
7.24
7.24
7.23
7.19
7.19
7.17
7.17
7.02
7.00
5.41
5.41
5.22
5.21
5.21
5.21
5.03
5.01
5.00
4.98
4.92
4.90
4.86
4.85
4.73
4.72
4.69
4.66
4.62
4.60
4.50
4.48
4.25
3.99
3.88
3.82
3.80
3.80
3.59
3.57
3.57
3.50
2.10
1.91
1.91
1.89

13k (^1H NMR, 500MHz, CDCl_3)



13k (^{13}C NMR, 126MHz, CDCl_3)




13k


—192.18
—170.99
—169.99
—169.72
—169.55
—164.44
—138.22
—138.07
—131.65
—128.67
—128.52
—128.33
—128.18
—127.86
—127.54
—127.44
—114.31

—105.31




—98.10
—84.69
81.97
77.16
75.34
75.31
74.61
73.67
69.20
69.03
69.01
65.26
61.71
57.37
55.67


20.93
20.77
20.74
20.59








13k (^1H - ^{13}C Coupled HSQC)







13k (¹H-¹H NOESY)




15 (¹H NMR, 500MHz, CDCl₃)




15




15 (¹³C NMR, 126MHz, CDCl₃)




15




16 (¹H NMR, 500MHz, CDCl₃)



16



16 (¹³C NMR, 126MHz, CDCl₃)



16

—193.27

—171.96

134.61

129.89

129.44

126.87

—111.51

—77.16

—70.58

—44.59

26.95


25.95

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10


f1 (ppm)

251


17 (¹H NMR, 500MHz, CDCl₃)




17




—203.53
17 (^{13}C NMR, 126MHz, CDCl_3)




17






17 (¹H-¹³C Coupled HSQC)




17


$J = 144 \text{ Hz}$



18 (¹H NMR, 500MHz, CDCl₃)




18




138.60
138.01
137.89
137.16
128.64
128.59
128.55
128.52
128.27
128.19
128.17
128.10
128.04
128.03
127.94
127.81
98.85
81.82
79.47
78.74
77.16
75.97
75.26
74.01
73.71
73.41
71.01
55.85


203.57

18 (¹³C NMR, 126MHz, CDCl₃)




18






18 (^1H - ^{13}C Coupled HSQC)




18

$J = 151 \text{ Hz}$




7.35
7.35
7.33
7.32
7.32
7.31
7.31
7.30
7.27
7.26
7.25
4.84
4.83
4.82
4.80
4.76
4.74
4.65
4.62
4.61
4.59
4.58
4.55
4.53
4.52
4.51
4.49
4.21
4.20
4.18
4.15
4.15
4.14
4.13
4.12
3.78
3.78
3.77
3.76
3.70
3.69
3.52
1.43
1.41


19 (^1H NMR, 500MHz, CDCl_3)



19





—203.95
19 (^{13}C NMR, 126MHz, CDCl_3)




19

138.53
138.31
138.07
128.47
128.32
127.92
127.91
127.84
127.81
110.89
—101.31
78.53
77.16
75.59
74.55
74.08
73.85
73.37
73.34
72.79
65.80
57.90
26.06
25.60






19 (^1H - ^{13}C Coupled HSQC)




19


$J = 144 \text{ Hz}$




20 (^{13}C NMR, 126MHz, CDCl_3)




—202.82 —172.88
138.43 138.22 137.86 128.49 128.46 128.36 127.93 127.90 127.83 111.10 —100.93
77.99 77.16 75.48 74.53 73.80 73.53 73.30 72.72 69.80 —58.03 —40.47 26.86 25.89







20 (¹H-¹³C Coupled HSQC)




20

J = 147 Hz






21 (^{13}C NMR, 126MHz, CDCl_3)




21

143.51
138.78
138.77
138.39
138.33
128.45
128.44
128.39
128.37
127.98
127.96
127.91
127.81
127.74
127.67
127.50
— 115.04
100.56
77.16
76.10
75.72
74.20
74.03
73.72
73.13
72.36
71.87
70.64
— 57.30







21 (¹H-¹³C Coupled HSQC)




21




22 (^{13}C NMR, 126MHz, CDCl_3)




22






22 (¹H-¹³C Coupled HSQC)




22


J = 144 Hz



23 (¹H NMR, 500MHz, CDCl₃)




23 (^{13}C NMR, 126MHz, CDCl_3)




23


143.25
138.90
138.43
138.35
128.59
128.52
128.46
128.42
128.19
128.12
128.03
128.02
127.73
127.69
127.66
— 116.30

98.26
82.21
81.47
80.03
77.16
75.98
74.95
73.49
72.48
71.52
70.61
— 55.34






23 (¹H-¹³C Coupled HSQC)




23

J = 150 Hz




7.36
7.36
7.35
7.33
7.33
7.32
7.31
7.30
7.30
7.29
7.29
7.28
7.27
7.27
7.22
7.22
7.21
7.20
4.83
4.80
4.68
4.56
4.54
4.51
4.50
4.48
4.46
4.42
4.39
4.39
4.00
4.00
3.99
3.98
3.97
3.96
3.72
3.71
3.71
3.69
3.68
3.68
3.66
3.62
3.62
3.57
3.57
3.55
3.55
3.46
2.29
2.29
2.28
2.27
2.26
1.85
1.84
1.83
1.82

24 (¹H NMR, 500MHz, CDCl₃)




24




138.82
138.75
138.32
138.13
128.45
128.43
128.40
128.14
128.04
127.96
127.82
127.78
127.53
100.31
77.16
76.98
75.54
73.95
73.57
72.98
72.90
71.85
70.12
66.86
56.99


—32.27

24 (¹³C NMR, 126MHz, CDCl₃)




24






24 (¹H-¹³C Coupled HSQC)




24


$J = 142 \text{ Hz}$



25 (^1H NMR, 500MHz, CDCl_3)



25




138.66
138.23
137.74
128.58
128.55
128.51
128.05
128.03
127.94
109.00
— 100.89


78.43
77.16
76.08
75.73
74.41
74.15
73.95
73.25
71.24
65.07
57.58


~26.49
~25.08
~19.40

25 (¹³C NMR, 126MHz, CDCl₃)




25








25 (¹H-¹³C Coupled HSQC)




25

$J = 143 \text{ Hz}$







26 (¹³C NMR, 126MHz, CDCl₃)




26






26 (¹H-¹³C Coupled HSQC)




26


J = 143 Hz




28 (¹H NMR, 500MHz, CDCl₃)




28




28 (¹³C NMR, 126MHz, CDCl₃)




28







29 (¹³C NMR, 126MHz, CDCl₃)




29






29 (¹H-¹³C Coupled HSQC)





29


$J = 151 \text{ Hz}$




30 (^1H NMR, 500MHz, CDCl_3)




30 (^{13}C NMR, 126MHz, CDCl_3)




138.50
138.19
137.98
128.55
128.50
128.19
128.05
127.98
127.91
127.88
— 100.47
77.16
75.49
73.93
73.72
73.45
73.15
73.02
71.95
— 63.00
— 57.39







30 (¹H-¹³C Coupled HSQC)




30




$J = 142$ Hz




31b (^{13}C NMR, 126MHz, CDCl_3)




31b






31b (¹H-¹³C Coupled HSQC)




31b


$J = 148 \text{ Hz}$




32 (¹H NMR, 500MHz, CDCl₃)



32





32 (¹³C NMR, 126MHz, CDCl₃)




32

138.75
138.14
128.58
128.44
127.96
127.95
127.87
127.72
— 102.74
78.42
77.16
73.56
72.60
71.51
70.97
63.30
57.16
— 32.26






32 (¹H-¹³C Coupled HSQC)




32




$J = 143 \text{ Hz}$


33 (¹H NMR, 500MHz, CDCl₃)



33




33 (¹³C NMR, 126MHz, CDCl₃)




33

137.81
136.85
128.71
128.60
128.33
128.05
128.03
127.84
-99.93
77.16
73.70
72.65
71.92
68.27
67.23
63.67
55.65




7.35
7.34
7.33
7.32
7.31
7.30
7.29
7.29
7.27
7.26
7.26
7.25
7.25
7.24
4.90
4.89
4.88
4.86
4.79
4.77
4.73
4.71
4.71
4.69
4.61
4.59
4.39
4.37
3.96
3.94
3.81
3.79
3.78
3.68
3.66
3.64
3.58
3.50
3.48
3.46
2.95
2.93
2.92
1.61
1.60
1.58
1.57
1.55
1.44
1.42
1.41
1.39
1.38
1.36
0.92
0.90
0.89


34 (^1H NMR, 500MHz, CDCl_3)



34



—196.54
34 (^{13}C NMR, 126MHz, CDCl_3)




34


138.48
138.40
137.86
128.48
128.45
128.29
128.19
127.96
127.92
127.82
127.77
104.85
83.95
81.72
79.83
79.66
77.16
75.87
75.27
74.87

—57.43


~31.33
~28.44
~22.10

—13.68






34 (¹H-¹³C Coupled HSQC)




34


$J = 146 \text{ Hz}$




35 (¹H NMR, 500MHz, CDCl₃)



35





35 (¹³C NMR, 126MHz, CDCl₃)




35

138.64
138.55
138.10
128.63
128.52
128.51
128.21
128.06
128.01
127.82
127.78
104.94
84.56
82.50
77.66
77.16
75.82
75.23
75.13
74.97
62.14
57.44






35 (¹H-¹³C Coupled HSQC)




35


$J = 143 \text{ Hz}$




36 (¹H NMR, 500MHz, CDCl₃)



36



36 (^{13}C NMR, 126MHz, CDCl_3)



36

191.76

135.13

129.28

129.21

128.02

78.95

77.16

72.14

70.82


69.30

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10


f1 (ppm)

305


39 (¹H NMR, 500MHz, CDCl₃)




39




39 (¹³C NMR, 126MHz, CDCl₃)





39







39 (¹H-¹³C Coupled HSQC)




40 (¹H NMR, 500MHz, CDCl₃)



40




—199.68
40 (^{13}C NMR, 126MHz, CDCl_3)




40

138.62
138.37
128.47
128.42
128.22
127.99
127.76
127.69
127.66
127.59
100.50
79.72
77.77
77.16
75.93
75.20
74.63
73.51
72.97
72.89
72.72
72.44
70.48
69.95
69.89
55.91







40 (¹H-¹³C Coupled HSQC)



40

$J = 143 \text{ Hz}$




f1 (ppm)


f2 (ppm)

7.84
7.84
7.83
7.79
7.77
7.76
7.75
7.73
7.72
7.67
7.66
7.63
7.62
7.62
7.54
7.49
7.48
7.47
7.46
7.46
7.44
7.42
7.41
7.40
7.39
7.35
7.33
7.32
7.30
7.26
7.25
5.16
5.13
5.05
5.02
5.00
4.98
4.96
4.94
4.93
4.87
4.86
4.84
4.81
4.78
4.61
4.57
4.55
4.54
4.36
4.34
4.15
4.13
3.91
3.89
3.87
3.64
3.63
3.61

41 (¹H NMR, 500MHz, CDCl₃)





41




198.38
138.58
136.20
135.56
133.43
133.27
133.06
133.03
128.51
128.19
128.07
128.03
127.99
127.80
127.79
127.68
127.12
126.52
126.47
126.12
126.04
125.95
125.91
125.86


105.61
84.49
82.06
78.93
77.71
77.16
75.97
75.82
75.33
74.89
73.34
73.08
70.30
70.01
69.74
57.43

41 (¹³C NMR, 126MHz, CDCl₃)






41 (¹H-¹³C Coupled HSQC)



41


$J = 144 \text{ Hz}$



f1 (ppm)


f2 (ppm)

42 (¹H NMR, 500MHz, CDCl₃)




42

7.44
7.43
7.42
7.38
7.37
7.36
7.35
7.35
7.34
7.30
7.29
7.27
7.26
7.25
7.23
7.22
7.21
7.14
7.13
7.12
5.06
5.04
4.96
4.94
4.92
4.87
4.72
4.70
4.66
4.65
4.64
4.59
4.59
4.58
4.58
4.32
4.30
4.24
4.12
4.10
4.08
4.05
3.99
3.97
3.95
3.89
3.87
3.53
3.10
3.09
3.08
3.07





42 (^{13}C NMR, 126MHz, CDCl_3)




42

139.70
139.08
138.11
129.06
128.46
128.38
128.30
127.73
127.44
127.41
126.99
103.93
80.87
79.32
77.69
77.16
76.22
75.03
74.33
73.20
72.90
70.09
69.99
69.85
63.68
56.50
55.10






42 (¹H-¹³C Coupled HSQC)





42

$J = 144 \text{ Hz}$



8.14
8.12
7.90
7.88
7.83
7.83
7.81
7.81
7.65
7.65
7.65
7.64
7.63
7.63
7.62
7.62
7.62
7.56
7.55
7.55
7.54
7.54
7.54
7.53
7.53
7.52
7.50
7.50
7.50
7.49
7.48
7.48
7.47
7.47

S1 (¹H NMR, 500MHz, CDCl₃)



11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0


f1 (ppm)

— 195.87
— 189.85


141.96
139.42
136.96
135.15
133.20
130.30
130.26
129.93
129.53
128.65
127.50
126.96

77.16


S1 (¹³C NMR, 126MHz, CDCl₃)




S1




S2 (¹H NMR, 500MHz, CDCl₃)



S2




S2 (¹³C NMR, 126MHz, CDCl₃)




S2

—188.85
—162.66
—155.45
135.29
131.13
130.24
129.85
129.62
129.36
127.54
124.90
120.40
117.52


77.16




S3 (¹H NMR, 400MHz, CDCl₃)




S3




S3 (¹³C NMR, 126MHz, CDCl₃)




S3



S4 (¹H NMR, 400MHz, CDCl₃)



S4



—189.47

—155.36

—149.96

—144.44

—135.23

—134.53

—129.88

—129.49

—127.12


—124.55

—120.89


—110.78

—77.16


S4 (¹³C NMR, 126MHz, CDCl₃)



S4




S5 (¹H NMR, 400MHz, CDCl₃)




S5

8.06
8.04
7.70
7.68
7.64
7.62
7.49
7.48
7.47
7.46
7.45
7.44
7.42
7.41
7.40
7.39

3.43
3.41
3.40
3.19
3.17
3.16




S5 (¹³C NMR, 126MHz, CDCl₃)




197.23
197.02
146.12
139.92
135.19
134.72
129.56
129.33
129.09
128.80
128.40
127.72
127.41
127.40


77.16
37.60
33.65




S6 (¹H NMR, 500MHz, CDCl₃)



S6



S6 (¹³C NMR, 126MHz, CDCl₃)



S6


141.23
136.84
134.58
129.61
129.32
129.18
128.19
127.88

-77.16


-53.88

-45.22


30.31
22.54
18.76




S7 (¹H NMR, 500MHz, CDCl₃)



S7



S7 (¹³C NMR, 126MHz, CDCl₃)




198.70
196.47
139.96
138.15
137.56
134.54
132.67
132.01
130.21
129.81
129.53
129.50
129.28
128.86
128.45
127.71


-77.16

-53.90

-18.76




S8 (¹H NMR, 500MHz, CDCl₃)




S8

7.39
7.37
7.35
7.33
7.31
7.30
7.29
7.28
4.99
4.97
4.96
4.94
4.71
4.69
4.67
4.65
4.16
4.14
3.72
3.72
3.71
3.70
3.70
3.68
3.68
3.55
3.42
3.41
3.40
3.38
3.38
3.36
3.34
3.32
3.31

2.15
1.55
1.54
1.52
1.50
1.49
1.35
1.34
1.32
1.31
1.29
1.28
0.97
0.95
0.94
0.92
0.91
0.89
0.88





S8 (¹³C NMR, 126MHz, CDCl₃)




S8

138.73
128.74
128.53
128.27
128.15
128.03
127.79
108.15
86.41
82.56
77.16
75.54
74.70
73.44
69.89
56.97
29.21
27.58
13.86
9.02







S8 (¹H-¹³C Coupled HSQC)




S8




J = 137 Hz

f1 (ppm)


f2 (ppm)




S9 (¹H NMR, 500MHz, CDCl₃)



S9




S9 (¹³C NMR, 126MHz, CDCl₃)




S9

142.06
138.51
138.23
128.52
128.47
128.09
127.88
127.72
101.66
101.59
77.42
77.16
73.60
73.25
71.04
-57.11




8.10
8.08
8.07
8.05
7.54
7.54
7.53
7.53
7.52
7.49
7.48
7.48
7.47
7.39
7.39
7.37
7.37
7.36
7.36
7.35
7.35
7.35
7.34
7.34
7.33
7.32
7.32
7.32
7.31
7.30
7.28
7.27
5.04
5.02
4.94
4.92
4.87
4.85
4.83
4.81
4.70
4.68
4.64
4.63
4.62
4.62
4.55
4.55
4.50
4.49
4.07
4.05
3.60
3.60
3.59
3.58
3.58
3.57
3.40


S10 (¹H NMR, 500MHz, CDCl₃)



S10




S10 (^{13}C NMR, 126MHz, CDCl_3)



S10

189.84
165.30
140.19
138.62
138.16
137.86
135.13
134.28
130.15
129.93
129.52
128.66
128.63
128.24
128.22
128.21
128.14
128.09
127.92
127.52
126.92


98.17
82.25
80.16
77.54
77.16
76.08
75.22
73.58
68.75
64.13
55.42




8.10
8.09
8.03
8.01
7.34
7.33
7.31
7.30
7.29
7.27
7.26
7.25
7.23
7.22
7.21
7.19
7.18
7.17
7.16
7.16
7.15

5.00
4.98
4.89
4.86
4.82
4.80
4.79
4.76
4.66
4.63
4.59
4.59
4.57
4.53
4.52
4.50
4.50
4.45
4.44
4.43
4.42
4.05
4.03
4.01
3.92
3.91
3.91
3.90
3.58
3.57
3.56
3.55
3.54
3.25

S11 (^1H NMR, 500MHz, CDCl_3)



S11



170.47
165.43
138.51
138.14
137.85
134.50
133.31
130.27
129.84
128.66
128.65
128.64
128.33
128.25
128.22
128.15
128.10
127.97
98.18
82.29
80.13
77.36
77.16
76.15
75.22
73.59
68.76
64.06
55.44

S11 (^{13}C NMR, 126MHz, CDCl_3)

